International Symposium

ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies

organized by

German AML Cooperative Group (AMLCG)
SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms

and

German Consortium for Translational Cancer Research (DKTK)

together with

Ludwig Maximilians-University Munich (LMU)
German Cancer Research Center (DKFZ)
HelmholtzZentrum München
German Research Center for Environmental Health
Comprehensive Cancer Center Munich (CCC München)
German Society for Hematology and Oncology (DGHO)
Working Group Internistische Onkologie in der Deutschen Krebsgesellschaft e.V. (AIO)
ELN Foundation – European LeukemiaNet

and

Verein für Leukämieforschung und –Therapie e.V.

February 24 – February 27, 2019
Munich, Germany

P R O G R A M
**ACUTE LEUKEMIAS XVII**
Biology and Treatment Strategies

**Organisation in Charge:**

Verein für Leukämieforschung und -Therapie e.V. Münster

**Cooperating Institutions:**

German AML Cooperative Group (AMLCG)

SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms

Klinikum der Universität München Medizinische Klinik und Poliklinik III

German Consortium for Translational Cancer Research (DKTK)

German Cancer Research Center (DKFZ)

HelmholtzZentrum München - German Research Center for Environmental Health

Comprehensive Cancer Center München (CCC München)

Deutsche Gesellschaft für Hämatologie und Onkologie (DGH0)

Working Group Internistische Onkologie in der Deutschen Krebgesellschaft e.V. (AIO)

ELN Foundation – European LeukemiaNet
Dear Colleagues:

The German AML Cooperative Group invites all professionals who are interested in getting informed about recent advances in the understanding of leukemia biology and the development of a personalized approach to leukemia therapy and the implementation of new discoveries into clinical practice to participate in the 16th International Symposium on ACUTE LEUKEMIAS held in Munich, February 24 – 27, 2019.

The symposium will again bring together a unique community of clinical scientists and researchers and will render all attendees the opportunity to discuss the most recent findings in basic research and results of clinical studies and network with the top international experts in these fields.

The scientific program will start on Sunday, February 24 with a main focus on basic research while the following days will concentrate on translational research and clinical studies.

You are cordially invited to use this forum to become updated on recent developments in the complex field of leukemia research and therapy. You may also take the opportunity to present your own data in the context of the poster and the best of free contribution sessions.

Satellite Symposia and Meet-the-Expert Sessions will deliver further chances to discuss advances and perspectives of basic science and treatment strategies.

The organizing committee and I am looking forward to an exciting Symposium on ACUTE LEUKEMIAS and I will be pleased to welcome you in Munich.

Yours

[Signature]

W. Hiddemann
SCIENTIFIC ORGANIZING COMMITTEE

Prof. Dr. W. Hiddemann, Munich
Prof. Dr. Dr. M. von Bergwelt, Munich
Prof. Dr. I. Jeremias, Munich
Prof. Dr. K. Spiekermann, Munich

Prof. Dr. M. Subklewe, Munich
PD Dr. K. Metzeler, Munich

NATIONAL SCIENTIFIC COMMITTEE

Prof. Dr. C.D. Baldus, Kiel
Prof. Dr. F. Bassemann, Munich
Prof. Dr. D. Beelen, Essen
Prof. Dr. Ch. Brandts, Frankfurt a.M.
Prof. Dr. L. Bullinger, Berlin
Prof. Dr. C. Buske, Ulm
Prof. Dr. H. Döhner, Ulm
Prof. Dr. J. Duyster, Freiburg
Prof. Dr. G. Ehninger, Dresden
Prof. Dr. T. Feuchtinger, Munich
Dr. N. Gökbuget, Frankfurt
Prof. Dr. K. Götze, Munich
Prof. Dr. W. Herr, Regensburg
Prof. Dr. M. Heuser, Hannover

Prof. Dr. D. Hoelzer, Frankfurt
Prof. Dr. W.K. Hofmann, Mannheim
Prof. Dr. K.A. Kreuter, Cologne
Prof. Dr. U. Krug, Leverkusen
Prof. Dr. H. Leonhardt, Munich
Prof. Dr. C. Müller-Tidow, Heidelberg
Prof. Dr. D. Niederwieser, Leipzig
Prof. Dr. D. Reinhart, Essen
Prof. Dr. M. Schrappe, Kiel
Prof. Dr. H. Serve, Frankfurt
Prof. Dr. M. Stelljes, Münster
Prof. Dr. Ch. Thiede, Dresden
Prof. Dr. A. Trumpp, Heidelberg
Prof. Dr. B. Wörmann, Berlin

INTERNATIONAL SCIENTIFIC COMMITTEE

Prof. Dr. M. Andreeff, Houston, USA
Prof. Dr. S.A. Armstrong, New York, USA
Prof. Dr. C. Bloomfield, Columbus, USA
Prof. Dr. A.K. Burnett, Cardiff, UK
Prof. Dr. R. Champlin, Houston, USA
Prof. Dr. J. DiPersio, St. Louis, USA
Prof. Dr. H. Dombret, Paris, F
Prof. Dr. E.H. Estey, Seattle, USA
Prof. Dr. P. Fenaux, Paris, F
Prof. Dr. W. Fibbe, Leiden, NL
Prof. Dr. R.A. Larson, Chicago, USA
Prof. Dr. R. Levine, New York, USA

Prof. Dr. F. Lo-Coco, Rome, I
Prof. Dr. B. Löwenberg, Rotterdam, NL
Prof. Dr. M. Manz, Zurich, CH
Prof. Dr. G.M. Ossenkoppele, Amsterdam, NL
Prof. Dr. G. Roboz, New York, USA
Prof. Dr. Russell, N.H., Nottingham, UK
Prof. Dr. M. Sanz, Valencia, E
Prof. Dr. C.A. Schiffer, Detroit, USA
Prof. Dr. R. Stone, Boston, USA

333 Prof. Dr. M. Tallman, New York, USA
POSTER AWARD COMMITTEE
Prof. Dr. K. Götze, Munich, DE
Prof. Dr. Krug, U., Leverkusen, DE

LEUKEMIA CLINICAL RESEARCH AWARD COMMITTEE
Prof. Dr. med. C. Baldus, Kiel, DE
Prof. Dr. med. C. Müller-Tidow, Heidelberg, DE
Prof. Dr. med. U. Platzbecker, Leipzig, DE
Prof. Dr. med. M. Schrapp, Kiel, DE
Prof. Dr. med. B. Wörmann, Berlin, DE

ORGANIZING OFFICE:
Beate Buske-Kosel, M.A.
Am Webstuhl 5
D-59227 Ahlen
Germany
Email: info@acute-leukemias.de

COORDINATING OFFICE:
Doris Braun
Department of Internal Medicine III
University Hospital Großhadern
Ludwig-Maximilians-University
Marchioninistraße 15
D-81377 Munich
Germany
Phone: +49-89-4400 43986
Fax: +49-89-4400 43970
Email: Doris.Braun@med.uni-muenchen.de
MAIN TOPICS

MS I: Epigenetic Changes in Acute Leukemias

MS II: Clonal Evolution of Acute Leukemias and Leukemic Stem Cells

MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis

MS IV: Novel Approaches and Targeted Therapies in AML

MS VI: Risk adapted Therapy of AML

MS VII: Biology and Treatment of APL

MS VIII: Relevance of MRD in Acute Leukemias

MS X: Immunotherapy for Acute Leukemias

MS XI: Biology and Treatment Strategies of ALL
TOPICS for FREE CONTRIBUTIONS

Leukemic Stem Cells

AML – Biology
AML – Therapy
ALL – Biology
ALL - Therapy
APL – Therapy

Pediatric Acute Leukemias

Immunotherapy of Acute Leukemias

Stem Cell Transplantation

Management of Elderly and Frail Patients

Supportive Therapy and Quality of Life

Leukemia Microenvironment
Interdisciplinary AGIHO EDUCATIONAL SYMPOSIUM
MAIN SESSIONS I - XI

Sunday, February 24, 2019
10.00-12.00: AGIHO Educational Symposium
(Infectious Diseases Working Party of the DGHO)
The Hematology Patient and the ICU

Sunday, February 24, 2019
12.30-14.15: MS I: Epigenetic Changes in Acute Leukemias
14.45-16.45: MS II: Clonal Evolution and Leukemic Stem Cells

Monday, February 25, 2019
08.30-09.45: OPENING SESSION
08.30-08.45: Welcome Address
08.45-09.45: Thomas Büchner Lecture
10.15-12.00: MS III: Genetic and Molecular Characterization of AML:
Novel Markers for Diagnosis and Prognosis
14.00-16.00: MS IV: Novel Approaches and Targeted Therapies in AML
16.00-18.00: Main Session V: Poster Viewing and Discussion

Tuesday, February 26, 2019
08.30-10.30: MS VI: Risk Adapted Therapy of AML
10.50-12.30: MS VII: Biology and Treatment of APL
14.00-16.00: MS VIII: Relevance of MRD in Acute Leukemias
16.30-17.30: Main Session IX: Prize Giving Ceremony Leukemia Clinical Research Award; Poster Awards and 3 of Best Free Contributions

Wednesday, February 27, 2019
08.30-10.30: MS X: Immunotherapy for Acute Leukemias
11.00-12.40: MS XI: Biology and Treatment Strategies of ALL
12.40-12.50 Closing Remarks
# Industry sponsored Satellite Symposia and Meet-the-Professor Sessions

**Sunday, February 24, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Sponsor</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00-18.00</td>
<td><strong>SATELLITE SYMPOSIUM I</strong></td>
<td>AMGEN AG</td>
<td>Lecture Hall III/IV</td>
</tr>
<tr>
<td>18.30-19.30</td>
<td><strong>SATELLITE SYMPOSIUM II</strong></td>
<td>AbbVie Deutschland GmbH</td>
<td>Lecture Hall III/IV</td>
</tr>
</tbody>
</table>

**Monday, February 25, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Sponsor</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00-13.45</td>
<td><strong>MTPI: Meet-the-Professor Session</strong></td>
<td>GILEAD Sciences GmbH</td>
<td>Lecture Hall VI</td>
</tr>
<tr>
<td>12.45-13.45</td>
<td><strong>SATELLITE SYMPOSIUM III</strong></td>
<td>Jazz Pharmaceuticals</td>
<td>Lecture Hall III/IV</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>SATELLITE SYMPOSIUM IV</strong></td>
<td>Daiichi Sankyo</td>
<td>Lecture Hall III/IV</td>
</tr>
<tr>
<td>18.15-19.15</td>
<td><strong>SATELLITE SYMPOSIUM V</strong></td>
<td>Roche Pharma GmbH</td>
<td>Lecture Hall III/IV</td>
</tr>
<tr>
<td>20.00-21.30</td>
<td><strong>EVENING SYMPOSIUM</strong></td>
<td>Vector Therapeutics, Inc.</td>
<td>LeMeridien</td>
</tr>
</tbody>
</table>

**Tuesday, February 26, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Sponsor</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00-14.00</td>
<td><strong>SATELLITE SYMPOSIUM VI</strong></td>
<td>ASTELLAS PharmaGmbH</td>
<td>Lecture Hall VI</td>
</tr>
<tr>
<td>16.30-17.30</td>
<td><strong>SATELLITE SYMPOSIUM VII</strong></td>
<td>Celgene GmbH</td>
<td>Lecture Hall III/IV</td>
</tr>
<tr>
<td>17.45-18.45</td>
<td><strong>SATELLITE SYMPOSIUM VIII</strong></td>
<td>Pfizer GmbH</td>
<td>Lecture Hall III/IV</td>
</tr>
</tbody>
</table>
### FACULTY

#### INVITED SPEAKERS – (alphabetical order)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azoulay, E.</td>
<td>Paris, F</td>
<td>AGIHO</td>
</tr>
<tr>
<td>Baldus, C.</td>
<td>Kiel, DE</td>
<td>MS XI</td>
</tr>
<tr>
<td>Berneman, Z.</td>
<td>Antwerpen, BE</td>
<td>MS X</td>
</tr>
<tr>
<td>Böll, B.</td>
<td>Cologne, DE</td>
<td>AGIHO</td>
</tr>
<tr>
<td>Brüggemann, M.</td>
<td>Kiel, DE</td>
<td>MS VIII</td>
</tr>
<tr>
<td>Brüggemann, R.</td>
<td>Nijmegen, NL</td>
<td>MTP I</td>
</tr>
<tr>
<td>Bullinger, L.</td>
<td>Berlin, DE</td>
<td>MS III, SAT III</td>
</tr>
<tr>
<td>Burnett, A.K.</td>
<td>Isle of Arran, UK</td>
<td>MS VI</td>
</tr>
<tr>
<td>Buske, Ch.</td>
<td>Ulm, DE</td>
<td>MS II</td>
</tr>
<tr>
<td>Daver, N.</td>
<td>Houston, TX, USA</td>
<td>MS X</td>
</tr>
<tr>
<td>Delwel, R.</td>
<td>Rotterdam, NL</td>
<td>MS I</td>
</tr>
<tr>
<td>DiNardo, C.</td>
<td>Houston, TX, USA</td>
<td>MS IV</td>
</tr>
<tr>
<td>DiPersio, J.</td>
<td>St. Louis, MO, USA</td>
<td>Thomas Büchner Lecture</td>
</tr>
<tr>
<td>Döhner, H.</td>
<td>Ulm, DE</td>
<td>MS IV, SAT VII</td>
</tr>
<tr>
<td>Dombret, H.</td>
<td>Paris, F</td>
<td>MS VI, SAT VII</td>
</tr>
<tr>
<td>Enver, T.</td>
<td>London, UK</td>
<td>MS XI</td>
</tr>
<tr>
<td>Figueroa, M.</td>
<td>Miami, FL, USA</td>
<td>MS I</td>
</tr>
<tr>
<td>Gerstung, M.</td>
<td>Hinxton, UK</td>
<td>MS III</td>
</tr>
<tr>
<td>Gill, S.I.</td>
<td>Philadelphia, PA, USA</td>
<td>MS X</td>
</tr>
<tr>
<td>Gökbuget, N.</td>
<td>Frankfurt, DE</td>
<td>MS XI</td>
</tr>
<tr>
<td>Götte, K.</td>
<td>Munich, DE</td>
<td>SAT VI</td>
</tr>
<tr>
<td>Hellstrand, K.</td>
<td>Gothenburg, SE</td>
<td>Evening Symposium</td>
</tr>
<tr>
<td>Huntly, B.</td>
<td>Cambridge, UK</td>
<td>MS I</td>
</tr>
<tr>
<td>Itzykson, R.</td>
<td>Paris, F</td>
<td>MS III</td>
</tr>
<tr>
<td>Jabbour, E.J.</td>
<td>Houston, TX, USA</td>
<td>MS XI</td>
</tr>
<tr>
<td>Jaiswal, S.</td>
<td>Stanford, CA, USA</td>
<td>MS II</td>
</tr>
<tr>
<td>Kiehl, M.</td>
<td>Frankfurt/O., DE</td>
<td>AGIHO</td>
</tr>
<tr>
<td>Kochanek, M.</td>
<td>Cologne, DE</td>
<td>AGIHO</td>
</tr>
<tr>
<td>Konopleva, M.</td>
<td>Houston, TX, USA</td>
<td>MS III, SAT II, SAT V</td>
</tr>
<tr>
<td>Lancet, J.E.</td>
<td>Rochester, NY, USA</td>
<td>MS VI</td>
</tr>
<tr>
<td>Larson, R.</td>
<td>Chicago, IL, USA</td>
<td>MS XI</td>
</tr>
<tr>
<td>Lengfelder, E.</td>
<td>Mannheim, DE</td>
<td>MS VII</td>
</tr>
</tbody>
</table>
### FACULTY

**INVITED SPEAKERS** (alphabetical order)

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Symposiums</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levis, M.J.</td>
<td>Baltimore, MD, USA</td>
<td>MS IV, SAT IV</td>
</tr>
<tr>
<td>Lo Coco, F.</td>
<td>Rome, I</td>
<td>MS VII</td>
</tr>
<tr>
<td>Majeti, R.</td>
<td>Stanford, CA, USA</td>
<td>MS II</td>
</tr>
<tr>
<td>Martner, A.</td>
<td>Gothenburg, SE</td>
<td>Evening Symposium</td>
</tr>
<tr>
<td>Melnick, A.</td>
<td>New York, NY, USA</td>
<td>MS I</td>
</tr>
<tr>
<td>Metzeler, K.</td>
<td>Munich, DE</td>
<td>MS III</td>
</tr>
<tr>
<td>Müller-Tidow, C.</td>
<td>Heidelberg, DE</td>
<td>MS I, SAT VIII</td>
</tr>
<tr>
<td>Mughal, T.I.</td>
<td>Boston, MA USA</td>
<td>SAT V</td>
</tr>
<tr>
<td>Oellerich, Th.</td>
<td>Frankfurt, DE</td>
<td>MS IV</td>
</tr>
<tr>
<td>Ossenkoppele, G.</td>
<td>Amsterdam, NL</td>
<td>MS VIII</td>
</tr>
<tr>
<td>Platzbecker, U.</td>
<td>Leipzig, DE</td>
<td>MS VII, SAT II</td>
</tr>
<tr>
<td>Reinhardt, D.</td>
<td>Essen, DE</td>
<td>MS VI</td>
</tr>
<tr>
<td>Roboz, G.</td>
<td>New York, NY, USA</td>
<td>MS X</td>
</tr>
<tr>
<td>Röllig, Ch.</td>
<td>Dresden, DE</td>
<td>MS VI</td>
</tr>
<tr>
<td>Rössig, C.</td>
<td>Münster, DE</td>
<td>MS X</td>
</tr>
<tr>
<td>Russell, N.G.</td>
<td>Nottingham, UK</td>
<td>MS VIII</td>
</tr>
<tr>
<td>Schlenk, R.</td>
<td>Heidelberg, DE</td>
<td>SAT IV</td>
</tr>
<tr>
<td>Schröder, Th.</td>
<td>Düsseldorf, DE</td>
<td>SAT VI</td>
</tr>
<tr>
<td>Shlush, L.</td>
<td>Rehovot, ISL</td>
<td>MS II</td>
</tr>
<tr>
<td>Staudinger, T.</td>
<td>Vienna, A</td>
<td>AGIHO</td>
</tr>
<tr>
<td>Stelljes, M.</td>
<td>Münster, DE</td>
<td>MS VI</td>
</tr>
<tr>
<td>Stone, R.M.</td>
<td>Boston, MA, USA</td>
<td>MS IV</td>
</tr>
<tr>
<td>Subklewe, M.</td>
<td>Munich, DE</td>
<td>MS X, SAT I, SAT VIII</td>
</tr>
<tr>
<td>Tallman, M.S.</td>
<td>New York, NY, USA</td>
<td>MS VII, SAT III</td>
</tr>
<tr>
<td>Topp, M.</td>
<td>Würzburg, DE</td>
<td>SAT I</td>
</tr>
<tr>
<td>Trumpp, A.</td>
<td>Heidelberg, DE</td>
<td>MS II</td>
</tr>
<tr>
<td>Valk, P.</td>
<td>Rotterdam, NL</td>
<td>MS VIII</td>
</tr>
<tr>
<td>von Bonin, M.</td>
<td>Dresden, DE</td>
<td>MS VIII</td>
</tr>
<tr>
<td>Vyas, P.</td>
<td>Oxford, UK</td>
<td>MS II</td>
</tr>
<tr>
<td>Walter, R.</td>
<td>Seattle, WA, USA</td>
<td>MS VIII</td>
</tr>
<tr>
<td>Wei, A.</td>
<td>Melbourne, VIC, AUS</td>
<td>MS IV</td>
</tr>
<tr>
<td>Zhu, H.-H.</td>
<td>Beijing, CHN</td>
<td>MS VII</td>
</tr>
</tbody>
</table>
FACULTY

INVITED CHAIRPERSONS (alphabetical order)

Andreeff, M., Houston, TX, USA     MS IV
Bergwelt, von, M., Munich, DE      MS X
Biondi, A., Monza, I               MS X
Bloomfield, C., Columbus, OH, USA  MS III
Buccisano, F., Rome, I             MS VIII
Bullinger, L., Berlin DE           SAT VI, SAT VIII
Creutzig, U., Hannover, DE         MX IX
Duyster, J., Freiburg, DE          MS III
Enard, W., Munich, DE              MS II
Estey, E., Seattle, WA, USA        MS VI
Fenaux, P., Paris, F               MS VII
Götze, K., Munich, DE              Poster Session Award Committee
Hiddemann, W., Munich, DE          SAT IV, SAT V, Evening Symposium
Hofmann, W.,K., Mannheim, DE       MS VII
Klussmann, J.-H., Halle, DE        MS VI
Kreuzer, K.-A., Cologne, DE        MS VIII
Krug, U., Leverkusen, DE           Poster Session Award Committee
Lengerke, C., Basel, CH             MS II
Löwenberg, B., Rotterdam, NL       MS I
Maschmeyer, G., Potsdam, DE        AGIHO
Metzeler, K., Munich, DE           SAT VII
Ostermann, H., Munich, DE          AGIHO
Plass, Ch., Heidelberg, DE         MS I
Ritter, J., Münster, DE            MS IX
Schiffer, Ch. A., Detroit, IL, USA  MS XI, Thomas Büchner Lecture
Schrapp, M., Kiel, DE              MS XI
Serve, H., Frankfurt, DE           MS IV
Spiekermann, K., Munich, DE        MS VII
EDUCATIONAL SYMPOSIUM of the AGiHO
(supported by a grant by GILEAD Sciences GmbH)
The Hematology Patient and the ICU

10.00-12.00 Interdisciplinary Educational Symposium
Arbeitsgemeinschaft Infektionen der DGHO (AGiHO)
(Infectious Diseases Working Party of the DGHO)
(Lecture Hall III/IV)

Co-Chairs:
H. Ostermann, Munich, DE
G. Maschmeyer, Potsdam, DE

10.00-10.10 Introductory Remarks and Welcome Address
G. Maschmeyer, Potsdam, DE

10.10-10.30 E. Azoulay, Paris, F
Hematology and ICU – Still an Unmet Need?

10.30-10.50 T. Staudinger, Vienna, A
ECMO in Hematology

10.50-11.10 B. Böll, Cologne, DE
ICE meets Immuno Oncology

11.10-11.30 M. Kiehl, Frankfurt/O, DE
Guideline 2018: ICU (DGHO/DGIN/ÖGIAN)

11.30-11.50 M. Kochanek, Cologne, DE
Guideline 2018: Sepsis (AgIHO)

11.50-12.00 Final Remarks

12.00-12.30 COFFEE BREAK
SUNDAY, February 24, 2019

MAIN PROGRAM

12.30-14.15  MS I: Epigenetic Changes in Acute Leukemias

Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
B. Löwenberg, Rotterdam, NL
Ch. Plass, Heidelberg, DE

12.30-12.50  A. Melnick, New York, NY, USA
Epigenetic Heterogeneity

12.50-13.10  M.E. Figueroa, Miami, FL, USA
Epigenetic Signatures in AML

13.10-13.30  R. Delwel, Rotterdam, NL
Transcription Factor Alterations in AML

13.30-13.50  C. Müller-Tidow, Heidelberg, DE
Targeting of Epigenetic Resistance Mechanisms in AML

13.50-14.10  B. Huntly, Cambridge, UK
Targeting Epigenetic Mechanisms / LSCs; Enhancer Deregulation

14.15-14.45  COFFEE BREAK
14.45-16.45 MS II: Clonal Evolution and Leukemic Stem Cells
Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
C. Lengerke, Basel, CH
W. Enard, Munich, DE

14.45-15.05 S. Jaiswal, Stanford, CA, USA
Clonal Hematopoiesis of Indeterminate Potential

15.05-15.25 R. Majeti, Stanford, CA, USA
Preleukemic Stem Cells

15.25-15.45 L. Shlush, Rehovot, ISL
Predicting Leukemia Development from Preleukemic Clonal
Hematopoiesis

15.45-16.05 A. Trumpp, Heidelberg, DE
Linking Metabolic Clues to Epigenomics in AML Stem Cells

16.05-16.25 Ch. Buske, Ulm, DE
PIWIL-Like Genes in Acute Myeloid Leukemia

16.25-16.45 P. Vyas, Oxford, UK
Clonal Evolution under IDH Inhibitor Therapy

16.45-17.00 COFFEE BREAK
**17.00-18.00   SATELLITE SYMPOSIUM I**  
Industry sponsored Satellite (AMGEN GmbH)  
*Lecture Hall III* (Overflow Rooms: LHs IV+V)  

*Targeted Therapy of Acute Leukemia: Present Achievements and Future Potential*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00-17.05</td>
<td>M. Topp, Würzburg, DE</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>17.05-17.30</td>
<td>M. Topp, Würzburg, DE</td>
<td><em>The Present: T-Cell Engaging Immunotherapy for ALL</em></td>
</tr>
<tr>
<td>17.30-17.55</td>
<td>M. Subklewe, Munich, DE</td>
<td><em>The Future: Bispecific Antibody Constructs for the Treatment of AML</em></td>
</tr>
<tr>
<td>17.55-18.00</td>
<td>M. Subklewe, Munich, DE</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

**18.00-18.30   COFFEE BREAK**
### 18.30-19.30  SATELLITE SYMPOSIUM II
Industry sponsored Satellite (AbbVie Deutschland GmbH)
Lecture Hall III (Overflow Rooms: LHs IV+V)

*Changing the Goals in AML: Optimizing Therapeutic Approaches for the Older Patients*

- **18.30-18.40**  U. Platzbecker, Leipzig, DE
  Welcome and Introduction

- **18.40-18.50**  U. Platzbecker, Leipzig, DE
  Emerging Agents for the treatment of Patients with AML

- **18.50-19.00**  M. Konopleva, Houston, TX, USA
  Targeting Appoptosis in AML

- **19.00-19.10**  M. Konopleva, Houston, TX, USA
  Strategies to overcome Resistance of Emerging Agents

- **19.10-19.20**  U. Platzbecker, Leipzig, DE
  From Bench to Bedside: Practical Considerations for the older Patient with AML

- **19.20-19.25**  Audience Q&A – All

- **19.25-19.30**  Summary and Close
  U. Platzbecker, Leipzig, DE

### 20.00-22.30  Welcoming Reception at LeMeridien  
(Details see page 51)

A free-of-charge Shuttle Bus Service will be available for all participants joining the Welcome Reception at LeMeridien after the end of Satellite II starting from the symposium venue (Back entrance Hörsaaltrakt; Details will be announced on site)
M O N D A Y, February 25, 2019

08.30-09.45 OPENING SESSION

08.30-08.45 WELCOME ADDRESS
W. Hiddemann, Munich, DE
Symposium Chairman
Lecture Hall III (Overflow Rooms: LHs IV+V)

08.45-09.45 THOMAS-BÜCHNER LECTURE
Lecture Hall III (Overflow Rooms: LHs IV+V)

Introduction
Ch. A. Schiffer, Detroit, IL, USA

J. DiPersio, St. Louis, MO, USA
From Cell Kinetics to Targeted Therapy in AML

09.45-10.15 COFFEE BREAK
MONDAY, February 25, 2019

10.15-12.00 MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis
Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
M. Björkholm, Stockholm, SE
M. Heuser, Hannover, DE

10.15-10.35 M. Gerstung, Hinxton, UK
*Genetic Landscape of AML and its Relevance for Treatment*

10.35-10.55 R. Itzykson, Paris, F
*Clonal Interference of Signaling Mutations in AML*

10.55-11.15 L. Bullinger, Berlin, DE
*Precision Medicine in AML – Fiction or Reality?*

11.15-11.35 K. Metzeler, Munich, DE
*Pretreatment Risk Stratification of AML - ELN and Beyond*

11.35-12.00 M. Konopleva, Houston, TX, USA
*Targeting BCL2*

12.00-14.00 LUNCH BREAK
MONDAY, February 25, 2019

13.00-14.00 LUNCH SESSIONS

13.00-13.45 MTPI: Meet-the-Professor Session
Industry sponsored Session (GILEAD Sciences GmbH)
(Lecture Hall VI)

Drug Interactions: Putting Success of New Drugs at Risk?
R. Brüggemann, Nijmegen, NL

12.45-13.45 SATELLITE SYMPOSIUM III
Industry sponsored Satellite (Jazz Pharmaceuticals)
Lecture Hall II (Overflow Rooms: LHs IV/V)

High-Risk AML: WHO Knows? Improving Outcomes in these Patients

12.45-12.50 Welcome and Introduction
L. Bullinger, Berlin, DE

12.50-13.10 Diagnosing High-Risk AML: *WHO and What?
L. Bullinger, Berlin, DE
- Clinical and Biological Heterogeneity of AML (Cytogenetics and Genomics)
- Overview of different classification systems
- Therapy related AML (t-AML)
  - Pathogenesis, clinical and genomic features, prognosis
- AML with Myelodysplasia Related Changes (AML-MRC)
  - WHO 2016 classification
  - Pathogenesis, clinical and genomic features, prognosis

13.10-13.30 Improving Outcomes in High-Risk AML
M.S. Tallman, New York, NY, USA
- Patient Case Study
- Trial Data Included Throughout Presentation

13.30-13.45 Q & A
Monday, February 25, 2019

14.00-16.00  **MS IV: Novel Approaches and Targeted Therapies in AML**
Lecture Hall III (Overflow Rooms LHs IV+V)

**Co-Chairs:**
M. Andreeff, Houston, TX, USA
H. Serve, Frankfurt, DE

14.00-14.20  **A. Wei, Melbourne, AUS**
*Venetoclax and Novel Combinations*

14.20-14.40  **R.M. Stone, Boston, MA, USA**
*Midostaurin Use in AML – RATIFY and Beyond*

14.40-15.00  **M.J. Levis, Baltimore, MD, USA**
*New FLT3 Inhibitors*

15.00-15.20  **Th. Oellerich, Frankfurt, DE**
*SYK Inhibitors in AML*

15.20-15.40  **H. Döhner, Ulm, DE**
*Molecular Targeted Therapies in AMLSG Portfolio*

15.40-16.00  **C. DiNardo, Houston, TX, USA**
*IDH1 and IDH2 Inhibitors*

16.00-18.00  **MS V: Poster Viewing and Discussion Session**
Posters see pages 32 - 46

(Posts will be presented on the Upper Floor of the symposium venue. A cheese and wine tasting is organized, where a great variety of Bavarian cheese will be served).

All poster presenters are expected to participate in MS V to allow all participants and members of the jury to talk to the presenters and have a personal scientific exchange about their poster(s).
17.00-18.00  **SATELLITE SYMPOSIUM IV**  
Industry sponsored Satellite (Daiichi Sankyo Oncology Europe GmbH)  
**Lecture Hall III** (Overflow Rooms: LHs IV+V)  

**FLT3/Targeted Therapy / Future of AML Therapy**

**Chair:**  
W. Hiddemann, Munich, DE

17:00–17:05  **Welcome and Introduction**  
W. Hiddemann, Munich DE

17:05–17:25  **R. Schlenk, Heidelberg, DE**  
*Targeted Therapy in AML: What do the Guidelines tell us?*

17:25–17:45  **M.J. Levis, Baltimore, USA**  
*Targeted Therapy in AML: Where does the Science guide us?*

17:50–18:00  **Panel Discussion and Closing Remarks**  
W. Hiddemann, Munich, DE
MONDAY, February 25, 2019

18.15-19.15  SATELLITE SYMPOSIUM V
Industry sponsored Satellite (Roche Pharma GmbH)
Lecture Hall III (Overflow Rooms: LHs IV+V)

Towards Next Generation AML Therapy

Chair:
W. Hiddemann, Munich, DE

18.15 -18.20  Introduction
W. Hiddemann, Munich, DE

18.20 -18.45  M. Konopleva, Houston, TX, USA
MDM2 Inhibition as a New Treatment Approach in AML

18.45-19.05  T.I. Mughal, Boston, MA, USA
Optimizing Clinical Management of Acute Leukemias in 2019

19.05 -19.15  Panel Discussion

After the end of Satellite Symposium V Vector Therapeutics invite all interested ISALXVII participants to join their Evening Symposium at LeMeridien (program next page).
A free-of-charge shuttle bus service will take all persons interested in this evening symposium directly to LeMeridien
M O N D A Y, February 25, 2019

20.00-21.00 EVENING SYMPOSIUM
(Vector Therapeutics)
LeMeridien

(A free-of-charge Shuttle Bus Service will be available for all participants joining the Evening Symposium at LeMeridien after the end of Satellite V starting from the symposium venue (Back entrance Hörsaaltrakt; Details will be announced on site)

Preventing AML Relapse: The Role of Immunotherapy

Chair:
W. Hiddemann, Munich, DE

19.30 -20.00 Welcome Reception – Drinks & Food

20.00 -20.10 Introduction
W. Hiddemann, Munich, DE

20.10-20.25 Highlights & Key Results:
Immune Activation during Immunotherapy with Ceplene/IL-2
Implications for Relapse risk and Survival in AML
Anna Martner, Gothenburg, SE

20.25-20.40 Highlights & Key results:
Relapse Prevention by Ceplene/IL-2 in Molecular Subgroups of AML
Kristoffer Hellstrand, Gothenburg, SE

20.40 -21.00 Roundtable / Panel Discussion
W. Hiddemann, Munich, DE

CLOSING REMARKS

PLEASE REGISTER via:
vectortherapeutics-symposium@iqvia.com
T U E S D A Y, February 26, 2019

08.30-10.30 MS VI: Risk Adapted Therapy of AML
Lecture Hall III (Overflow Rooms IV+V)

Co-Chairs:
H. Klusmann, Halle/S., DE
E. Estey, Seattle, WA, USA

08.30-08.50 H. Dombret, Paris, F
Prognostic Factors / Chemo vs Epigenetic Therapy in AML

08.50-09.10 J.E. Lancet, Rochester, NY, USA
Innovations in Conventional Chemotherapy (CPX 351)

09.10-09.30 A.K. Burnett, Isle of Arran, UK
Gemtuzumab in CBF AML

09.30-09.50 Ch. Röllig, Dresden, DE
Overlapping Targets - Prioritization of Risks or Multitargeting?

09.50-10.10 D. Reinhardt, Essen, DE
Risk Adapted Therapy of Childhood AML

10.10-10.30 M. Stelljes, Münster, DE
Remission Status Prior to Allogeneic HSCT: Does it Matter?

10.30-10.50 COFFEE BREAK
**TUESDAY, February 26, 2019**

**10.50-12.30**  
**MS VII: Biology and Treatment of APL**  
*Lecture Hall III (Overflow Rooms LHs IV+V)*

*Co-Chairs:*
K. Spiekermann, Munich, DE  
W.-K. Hofmann, Mannheim, DE

**10.50-11.10**  
**F. Lo Coco, Rome, I**  
*APL – Biology and Treatment*

**11.10-11.30**  
**U. Platzbecker, Leipzig, DE**  
*Current Studies in APL*

**11.30-11.50**  
**E. Lengfelder, Mannheim, DE**  
*AML-CG Trials in APL*

**11.50-12.10**  
**M.S. Tallman, New York, NY, USA**  
*Early Death: The Last Frontier in APL*

**12.10-12.30**  
**H.-H. Zhu, Beijing, CHN**  
*Oral Arsenic for the Treatment of APL*

**12.30-14.00**  
**LUNCH BREAK**
Satellite Symposium VI
Industry sponsored Session (ASTELLAS PHARMA GmbH)
Lecture Hall III (Overflow Rooms: LHs IV+V)

Progress in AML: The Present and the Future

Chair:
L. Bullinger, Berlin, DE

Welcome and Introduction
L. Bullinger, Berlin, DE

K. Götze, Munich, DE
Progress in AML: The Present

Th. Schröder, Düsseldorf, DE
Progress in AML: The Future

Discussion and Conclusion - All
L. Bullinger, Berlin, DE
TUESDAY, February 26, 2019

14.00-16.00 MS VIII: Relevance of MRD in Acute Leukemias
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
K.-A. Kreuzer, Cologne, DE
F. Buccisano, Rome, I

14.00-14.20 G. Ossenkoppele, Amsterdam, NL
MRD-Guided Therapy of AML

14.20-14.40 N. Russell, Nottingham, UK
Clinical Impact of MRD Monitoring in AML

14.40-15.00 R.B. Walter, Seattle, WA, USA
MRD before and after Stem Cell Transplantation

15.00-15.20 M. Brüggemann, Kiel, DE
MRD Assessment in ALL in Times of Targeted Therapies

15.20-15.40 P. Valk, Rotterdam, NL
MRD by NGS

15.40-16.00 M. von Bonin, Dresden, DE
MRD Harmonize Initiative: SAL & AMLCG

16.00-16.30 COFFEE BREAK
Tuesday, February 26, 2019

16.30-17.30  MS IX: Prize Giving Ceremony

Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
J. Ritter, Münster, DE
U. Creutzig, Hannover, DE

16.30-16.40  Poster Prizes:
Official Announcement of this Year’s 2 Poster Award Winners

16.40-17.10  3 Best of Free Contributions:
Official Announcement of this Year’s 3 Best of Free Contributions’ Winners followed by a 10 minutes’ presentation

16.40-16.50  The interruption of PPARγ/RXR function by PML-RARα or TRIB3 separately causes dyslipidemia in newly diagnosed APL or in anti-APL treated patients

Ke Li et al. (Poster #3)
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China

16.50-17.00  Anti-human CD117 CAR T-cells efficiently eliminate hematopoietic stem and CD117-positive AML cells

R. Myburgh et al. (Poster #72)
Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland

17.00-17.10  Extracellular ATP and CD39 regulates mitochondrial function and cytarabine resistance through intrinsic PKA-PGC1α pathway in acute myeloid leukemia

N. Arou et al. (Poster #55)
Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France ; University of Toulouse, F-31077 Toulouse, France

17.10-17.25  Leukemia Clinical Research Award 2019 (LCRA):
Official Announcement of the LCRA 2019 Laureate followed by a 15 minutes’ presentation

17.25-17.30  Final Remarks

17.30-17.45  COFFEE BREAK
TUESDAY, February 26, 2019

16.30-17.30 SATELLITE SYMPOSIUM VII
Industry sponsored Satellite (Celgene GmbH)
Lecture Hall III (Overflow Rooms LHs IV+V)

Deciphering AML Complexities: Prognosis and Treatment

Chair:
K. Metzeler, Munich, DE

16.30-16.35 Welcome and Introduction
K. Metzeler, Munich, DE

16.35-17.00 K. Döhner, Ulm, DE
How do Genetics of AML Patients influence Prognosis, Treatment Strategies and Follow-Up Today and Tomorrow?

17.00-17.25 H. Dombret, Paris, F
What Expectations do we have of AML Treatment Beyond Complete Remission?

17.25-17.30 Discussion and Close

17.30-17.45 COFFEE BREAK
TUESDAY, February 26, 2019

17.45-18.45  SATELLITE SYMPOSIUM VIII
(Pfizer GmbH)
Lecture Hall III (Overflow Rooms LHs IV+V)

*Changing Treatment Landscape in AML*

**Chair:**
L. Bullinger, Berlin, DE

17.45-17.50  Welcome
L. Bullinger, Berlin, DE

17.50-18.10  M. Subklewe, Munich, DE
*Targeting CD33 in AML*

18.10-18.15  Q & A

18.15-18.35  C. Müller-Tidow, Heidelberg, DE
*Emerging Treatment Strategies in AML*

18.35-18.40  Q & A

18.40-18.45  Conclusion
L. Bullinger, Berlin, DE

19.30-22.30  Social Evening and Informal Dinner at DEUTSCHES MUSEUM
(details see page 52)

A free-of-charge Shuttle Bus Service will be available for all participants joining the Welcome Reception at LeMeridien after the end of Satellite II starting from the symposium venue (Back entrance Hörsaaltrakt; Details will be announced on site)
WEDNESDAY, February 27, 2019

08.30-10.30 MS X: Immunotherapy for Acute Leukemias
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
M. von Bergwelt, Munich, DE
A. Biondi, Monza, I

08.30-08.50 G. Roboz, New York, NY, USA
TCR tg T Cells for Adoptive Therapy in Acute Leukemia

08.50-09.10 N.G. Daver, Houston, TX, USA
Checkpoint Inhibitor based Combination Approaches in AML/MDS

09.10-09.30 Z. Berneman, Antwerpen, NL
DC Vaccination in AML

09.30-09.50 M. Subklewe, Munich, DE
Harnessing the T-Cell Response in AML

09.50-10.10 S.I. Gill, Philadelphia, PA, USA
CART in AML

10.30-11.00 C. Rössig, Münster, DE
CART in ALL

10.30-11.00 COFFEE BREAK
W E D N E S D A Y , February 27, 2019

11.00-12.40  MS XI: Biology and Treatment Strategies in ALL
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
M. Schrappe, Kiel, DE
A. Schiffer, Detroit, MI, USA

11.00-11.20  T. Enver, London, UK
Embryonic Origins of ALL Leukemogenesis

11.20-11.40  R.A. Larson, Chicago, IL, USA
Overall Approach

11.40-12.00  E.J. Jabbour, Houston, TX, USA
Treatment Strategies in ALL

12.00-12.20  N. Gökbuget, Frankfurt, DE
Blina in MRD + ALL

12.20-12.40  C.D. Baldus, Kiel, DE
ALL Characteristics Specific for Relapse

12.40-12.50  CLOSING REMARKS
POSTERS

Poster Viewing:
Monday, February 25, 2019: 13.00 – 18.00
Tuesday, February 26, 2019: 09.00 – 18.00

Poster Viewing and Discussion Session:
Monday, February 25, 2019: 16.00 – 18.00 (MSV)

Prize Giving Ceremony: 3 of Best Free Contributions:
Tuesday, February 26, 2019: 16.30 – 17.30 (MSIX)

I. AML – BIOLOGY

(1) CLINICOPATHOLOGICAL COMPARISON OF EGFR EXPRESSING AND NON EXPRESSING ACUTE MYELOID LEUKAEMIA
S. Nath\(^1\), KK. Saikia\(^1\), J. Bhattacharyya\(^2\)
\(^1\)Department of Bioengineering and Technology, Gauhati University, Guwahati, Assam, India; \(^2\)Department of Clinical Haematology, Gauhati Medical College and Hospital, Guwahati, Assam, India

(2) UNEXPECTED PROPERTIES OF A NOVEL T(11;19) OUT-OF-FRAME MLL FUSION GENE IN EXPANDING HUMAN CD34+ BLOOD PROGENITOR CELLS RESEMBLING ACUTE MYELOMONOBLASTIC LEUKAEMIA AML M4/5
R. Windisch\(^1\), N. Pirschat\(^1\), S. Soliman\(^1\), L. Chen-Wichmann\(^1\), C. Kellner\(^1\), S. Setzer\(^1\), M. Shvartsman\(^1\), T. Herold\(^2\), A. Humpe\(^1\), P. A. Greif\(^2\) and C. Wichmann\(^1\)
\(^1\)Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich Germany; \(^2\)Department of Medicine III, University Hospital LMU Munich, Munich Germany

(3) THE INTERRUPTION OF PPAR\(\gamma\)/RXR FUNCTION BY PML-RAR\(\alpha\) OR TRIB3 SEPARATELY CAUSES DYSLIPIDEMIA IN NEWLY DIAGNOSED APL OR IN ANTI-APL TREATED PATIENTS
Ke Li\(^1\#\), Feng Wang\(^2\#\), Zhao-na Yang\(^2\#\), Zhuo-wei Hu\(^2\#\) and Hong-hu Zhu\(^3\#\)
\(^1\)Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China; \(^2\)State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College; \(^3\)Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China

(4) ROLE OF TRANSPORT PROTEINS AND ENZYMES IN RESISTANCE TO INDUCTION CHEMOTHERAPY IN AML
G. Rodríguez-Macías\(^1\), O. Briz\(^1\), M.C. Chillón\(^3\), C. Martínez-Laperche\(^2,4\), I. Buño\(^2,4\), M. González-Díaz\(^3\), JL. Díez-Martín\(^2,4\), J.J.G. Marin\(^1\), R.I.R. Macías\(^1\)
\(^1\)HEVEFARM, University of Salamanca, CIBERehd, IBSAL, Salamanca, Spain; \(^2\)Hospital General Universitario Gregorio Marañón, Madrid, Spain; \(^3\)Hematology, University Hospital Salamanca, IBSAL, CIBERONC, Salamanca, Spain; \(^4\)Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
(5) TARGETING THE METHYLTRANSFERASE ACTIVITY OF NSD1 IN NUP98-NSD1 POSITIVE LEUKEMIA AS A NOVEL THERAPEUTIC STRATEGY
1Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

(6) DISRUPTION OF CSF-1R SIGNALING INHIBITS GROWTH OF INV(16) AML
A. Simonis, N. Russkamp, C. M. Wilk, A.P.A. Theocharides, R. Myburgh, M. G. Manz
Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland

(7) IDENTIFICATION OF GENETIC, EPIGENETIC AND CELLULAR EVENTS IMPLICATED IN DISTINCT CLINICAL OUTCOMES OF DNMT3A mut AMLs
1Division of Stem Cells and Cancer, DKFZ, Heidelberg, Germany; 2Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg; 3UniversitätsKrebs Centrum (UCC), Medical Systems Biology Medical Faculty Carl Gustav Carus, TU Dresden; 4Charité - Universitätsmedizin Berlin; 5Institute for Medical Informatics and Biometry (IMB) Carl Gustav Carus Faculty of Medicine, TU Dresden; 6German Cancer Consortium, (DKTK)

(8) ACUTE MYELOID LEUKEMIA-ASSOCIATED MESENCHYMAL STROMAL CELLS (AMSCS) SUPPORT THE GROWTH OF AML CELLS AND CAN BE TARGETED BY DEXAMETHASONE AS A NOVEL APPROACH TO TREAT AML
Yahya S. Al-Matary, Maren Fiori, Lacramioara Botezatu, Dennis Heinrichs, Aniththa Thivakaran, Judith Schütte, Fatema Zami, Daria Frank, Pradeep Kumar Patnana, Ulrich Dührsen, Bertram Opalka, Georg Lenz, and Cyrus Khandanpour; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany; 2Department of Hematology, Westdeutsches Tumorzentrum, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

(9) THE ROLE OF GROWTH FACTOR INDEPENDENCE 1 (GFI1) IN LEUKEMIA EVOLUTION, GENOME STABILITY AND DNA
D. Frank, Y. Al-Matary, A. Thivakaran, J. Schütte, U. Dührsen, and C. Khandanpour
1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany; 2Department of Hematology, Westdeutsches Tumorzentrum, University Hospital Essen, Germany

(10) SINGLE CELL GENOTYPING AND TRANSCRIPTOME ANALYSIS OF AML PATIENTS WITH SUBCLONAL FLT3 MUTATIONS
Johannes W. Bagnoli, Lucas E. Wange, Ilse Valtierra, Daniel Richter, Aleksandar Janjic, Johanna Geuder, Christoph Ziegenhain, and Wolfgang Enard (* contributed equally)

(11) CD34+CD38- LEUKEMIC STEM CELL LOAD AT DIAGNOSIS PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA
1. Amsterdam UMC, VU University Medical Center, Dept. of Hematology, Amsterdam, The Netherlands, 2. Amsterdam UMC, VU University Medical Center, Dept. of Pediatric Oncology/Hematology, Amsterdam, The Netherlands
(12) WHOLE EXOME SEQUENCING IDENTIFIES RECURRENT SOMATIC MUTATIONS IN UPSTREAM OPEN READING FRAMES (uORFs) IN ACUTE MYELOID LEUKEMIA

T. Kischka¹, V. Shabardina¹, O. Klaas², W. Makalowski¹, W.E. Berdel², G. Lenz², C. Schliemann², and K. Wethmar²
¹Institute of Bioinformatics, Faculty of Medicine, University of Muenster, Germany; ²Department of Med. A, Hematology/Oncology, University Hospital Muenster, Germany

(13) MCL1 PLAYS AN ESSENTIAL ROLE FOR PATIENT’S AML, AS SHOWN BY INDUCIBLE KNOCKDOWN IN PDX MODELS IN VIVO

M. Carlet¹, J. Vergalli¹, BC Heckl¹, M. Schmidt-Supprian² and I. Jeremias¹,³,⁴,⁵,⁶
¹Department of Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Zentrum, Munich, Germany; ²III. Medizinische Klinik, Technische Universität München, Munich, Germany; ³Department of Pediatrics, Dr. von Hauner Children’s Hospital, LMU Munich, Munich, Germany; ⁴Department of Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Zentrum München, Munich, Germany; ⁵German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁶Partner Site Munich, German Consortium for Translational Cancer Research (DKTK), Munich, Germany

(14) FROM CELLULAR THERAPIES TO RNA-BASED APPROACHES AGAINST LEUKEMIA: DISTURBANCE OF THE C/EBPα-MIR-182 BALANCE IMPAIRS GRANULOCYTIC DIFFERENTIATION AND PROMOTES DEVELOPMENT OF ACUTE MYELOID LEUKEMIA

Gerhard Behre, Franziska Wilke, Johannes Küpper, Alena Renker, Paula Reichelt, and Uwe Platzbecker
Medical Clinic and Polyclinic 1 - Hematology and Cellular Therapy, Medical Oncology, Hemostaseology, University Hospital Leipzig, Liebigstr. 22, 04103 Leipzig, Germany (Email: gerhard.behre@medizin.uni-leipzig.de)

(15) GENE FUSION DETECTION BY RNA-SEQ IN ACUTE MYELOID LEUKEMIA (AML)

P. Kerbs¹,²,³, A.M. Nazeer Batcha⁵, S. Vosberg¹,²,³, D. Metzler⁴, Tobias Herold¹,²,³, P.A. Greif¹,²,³
¹Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; ²German Cancer Consortium (DKTK), partner site Munich, Germany; ³German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁴Department of Biology, LMU Munich, Planegg-Martinsried, Germany; ⁵Department of Medical Data Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany

(16) GATA2 ZF1 MUTANTS AFFECT ERYTHROID DIFFERENTIATION AND IMPACT ON CHEMOTHERAPY RESPONSE

G. Leubolt¹,²,³, E. Redondo Monte¹,²,³, A. Wilding¹,²,³, P. Kerbs¹,²,³, B. Tizazu¹, S. Dutta¹, M. Cusan¹, J. Bagnoli⁴, W. Enard⁴, W. Hiddemann¹,²,³, C. Wichmann⁵, G. Schotta⁶, P. A. Greif¹,²,³
¹Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany; ²German Cancer Consortium (DKTK), partner site Munich, Germany; ³German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁴Anthropology & Human Genomics, Department of Biology II, Ludwig-Maximilians-University, Munich; ⁵Department of Transfusion Medicine, Cell Therapeutics and Hemostasis, University Hospital, LMU Munich, Munich, Germany; ⁶Biomedical Center (BMC) of the LMU Munich, Germany

(17) ZBTB7A MUTATIONS IN ACUTE LEUKEMIA DEREGULATE LINEAGE COMMITMENT

E. Redondo Monte¹, A. Wilding¹, G. Leubolt¹, L. Hartmann¹, W. Hiddemann¹, L. Chen-Wichmann², C. Wichmann², P. A. Greif¹,³
¹Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; ²Department of Transfusion Medicine, Cell Therapeutics and Hemostasis, University Hospital, LMU Munich, Munich, Germany; ³German Cancer Consortium (DKTK), partner site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany
(18) TYROSINE KINASE ACTIVITY ARRAY TECHNOLOGY REVEALS THE EFFECT OF DASATINIB ON ACUTE MYELOID LEUKAEMIA CELL SIGNALING NETWORKS
A. González-Sánchez and K. Mills
Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, United Kingdom

(19) TREATMENT OF rMLL+ AML BY SIMULTANEOUS INHIBITION OF LSD1 AND MEK PATHWAY
A. Caroleo1, E. Redondo-Monte1, G. Leubold1, A. Wilding1, S. Armstrong2, M. von Bergwelt1, P.A. Greif1 & M. Cusan1
1Dept of Medicine III, LMU Munich; 2DFCI, Harvard Med. School, Boston, USA

(20) IRRADIATION OF MICROENVIRONMENT NEUTRALIZES EPIGENETIC THERAPY BY LSD1 INHIBITION IN MURINE AML MODEL
M. Cusan1, A. Caroleo1, E. Redondo-Monte1, G. Leubold1, A. Wilding1, S. Armstrong2, M. von Bergwelt1, P.A. Greif1
1Dept of Medicine III, LMU Munich; 2DFCI, Harvard Med. School, Boston, USA

(21) SELECTIVE INACTIVATION OF CANCER DRUGS BY SAMHD1 PROVIDES A MOLECULAR RATIONALE FOR THERAPEUTIC STRATIFICATION IN AML
C. Schneider,1* T. Oellerich,1,2* K. M. Knecht,3 D. Thomas,4 O. Buzovetsky,3 C. Schliemann,5 H. Bohnenberger,6 L. Angenendt,6 W. Hartmann,7 E. Wardelmann,7 S. Scheich,1 F. Comoglio,8 A. Wilke,1 P. Ströbel,7 H. Serve,1,2 G. Geisslinger,4,9 O. T. Keppler,10 Y. Xiong9 and J. Cinatl Jr11
1Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany.
2German Cancer Consortium/ German Cancer Research Center, Heidelberg, Germany.
3Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, USA.
4pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University of Frankfurt, Frankfurt, Germany.
5Department of Medicine A (Hematology, Oncology), University Hospital Münster, Germany.
6Institute of Pathology, University Medical Center, Göttingen, Germany.
7Gerhard Domagk Institute for Pathology, University Hospital Münster, Germany.
8Cambridge University Department of Haematology, Cambridge Institute of Medical Research, Cambridge, United Kingdom.
9Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group Translational Medicine and Pharmacology (TMP), Frankfurt, Germany.
10Max von Pettenkofer Institute, Virology, Faculty of Medicine, LMU München, Munich, Germany.
11Institute of Medical Virology, University of Frankfurt, Frankfurt, Germany

(22) A TARGETED NGS PANEL FOR COST-EFFECTIVE AND SENSITIVE DETECTION OF LEUKEMIC MARKERS IN AML PATIENT SAMPLES
D. Richter1, S. Krauß1, K.H. Metzeler2, W. Enard1
1Department Biology II, Ludwig-Maximilians University, Munich, Germany; 2Medizinische Klinik und Poliklinik III, LMU, Munich, Germany

(23) FUNCTIONAL CHARACTERIZATION OF THE G372V AND T454M MUTATIONS IN THE SPLICING FACTOR
V. L. Rocha1; G. B. Bidoia1; L. Z. Oliveira1; V. C. Arfelli1; L. Fröhlich Archangelo1
1Department of Cellular and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil
(24) LEUKEMOGENESIS IN SEVEN PATIENTS WITH DONOR CELL DERIVED MYELOID NEOPLASMS. WHOLE EXOME SEQUENCING REVEALS CLONAL DYNAMICS
Julia Suárez-González1,2, Juan Carlos Triviño3, Mi Kwon4, Ángela Figuera5, Guiomar Bautista6, Jose Antonio García Marco6, Antonio Balas7, José Luis Vicario7, Francisco José Ortúñom, Raúl Teruel9, José María Álamo9, Pascual Balsalobre9, José Luis Díez-Martín7,10, Carolina Martínez-Laperche4,5,8,9, Ismael Buño1,2,4,8. (*) Identical contribution
1Genomics Unit, Gregorio Marañón General University Hospital (HGUGM), Gregorio Marañón Health Research Institute (IiSGM), Spain. 2IiSGM, Spain. 3Sistemas Genómicos, Spain. 4HGUGM, Spain. 5La Princesa University Hospital, Spain. 6Puerta de Hierro General University Hospital, Spain. 7Madrid Blood Centre, Spain. 8Meseguer General University Hospital, Spain. 9CIALAB, Spain 10Complutense University of Madrid, Spain

(25) INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 ACTIVATES THE RETINOIC ACID DIFFERENTIATION PATHWAY IN ACUTE MYELOID LEUKEMIA
N. van Gils1, H.J.M.P. Verhagen1, A. rutten1, R.X. Menezes2, M. Tsui1, E. Dekens1, F. Denkers1, E. Vermue1, J.J.M. Janssen1, G.J. Ossenkoppele1 and L. Smit1
1Department of Hematology, 2Department of Epidemiology and Biostatistics, VU University Medical Center, Cancer Center Amsterdam, The Netherlands

(26) LONG-TERM DORMANCY IS REVERSIBLE IN PATIENTS’ AML CELLS GROWING IN MICE
S. Ebinger1, C. Zeller1, K. Spiekermann2,4, B. Vick1-3, I. Jeremias1,2,5
1Dept. AHS, Helmholtz Zentrum München, Germany; 2DKTK, Munich, Germany; 3DKFZ, Heidelberg, Germany; 4Dept. of Medicine III, LMU, Munich, Germany; 5Dept. of Pediatrics, Dr. von Hauner Childrens Hospital, LMU, Munich, Germany

(27) LOSS OF KDM6A CONFERS DRUG RESISTANCE IN AML
Sophie M. Stief1,2, Anna-Li Hanneforth1, Raphael Mattes1, Sabrina Weser1, Michela Carlet4, Wen-Hsin Liu6, Michael D. Bartoschek5, Helena Domínguez Moreno9, Binje Vick2,4, Bianka Ksienzyk1, Maja Rothenberg-Thurley1, Hilmar Quentmeier7, Wolfgang Hiddemann1,2, Klaus H. Metzeler1, Gunnar Schotta6, Sebastian Bultmann5, Irmela Jeremias2,4, Heinrich Leonhardt5, and Karsten Spiekermann1,3
1Department of Medicine III, University Hospital, LMU Munich Munich, Germany. 2German Cancer Consortium (DKTK), and 3German Cancer Research Centre (DKFZ), Heidelberg, Germany. 4Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum, Munich, Germany. 5Department of Biology II and Center for Integrated Protein Science Munich (CIPSM), Human Biology and Biolmaging, LMU, Martinsried, Germany. 6Biomedical Center and Center for Integrated Protein Science, LMU, Martinsried, Germany. 7Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany. 8Department of Pediatrics, Dr. von Hauner Children’s Hospital, LMU Munich, Munich, Germany

(28) DETECTION OF GERMLINE MUTATIONS BY NEXT GENERATION SEQUENCING IN MYELOID NEOPLASMS
C. Andrés1,2,*, J. Suárez1,2,*, N. Dorado4, D. Carbonell2,4, G. Rodríguez4, M. Chicano4, P. Muñiz2,4, M. Bastos4, M. Kwon4, P. Balsalobre4, JL. Díez2,4,10, C. Martínez2,4,*,I. Buño1,2,4,*. (*) Identical contribution
1Genomics Unit, Gregorio Marañón General University Hospital (HGUGM), Gregorio Marañón Health Research Institute (IiSGM), Spain. 2IiSGM, Spain. 4HGUGM, Spain. 10Complutense University of Madrid, Spain
(29) INFERENCE AND SIMULATION OF CLONAL PHYLOGENIES IN ACUTE MYELOID LEUKEMIA USING SINGLE-CELL RNA-SEQ
Ilse A. Valtierra-Gutiérrez [1], Veronika Stiegler [1], Charlotte W. van Noort [2], Beate Vieth [1], Johannes Bagnoli [1], Wolfgang Enard [1], Ines Hellmann [1]
[1] Anthropology and Human Genomics, Department Biology II, Faculty of Biology, Ludwig-Maximilians University Munich, Großhaderner Straße 2, 82152 Martinsried, Germany; [2] Department of Computer Science, VU University Amsterdam, Amsterdam 1081 HV, The Netherlands

(30) TARGETING miRNA-551B, A STEMNESS-LIKE MICRNORNA, TO ERADICATE AML (STEM) CELLS
Tània Martiáñez Canales, PhD¹, David C de Leeuw, PhD¹, Eline Vermue¹, Arjo Rutten¹, Fedor Denkers¹, Han JMP Verhagen¹, Jeroen JWM. Janssen, PhD¹, Gert J Ossenkoppele, PhD¹, C. Jimenez, PhD², and Linda Smit, PhD¹
¹Department of Hematology, ²Proteomics facility, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands

(31) SINGLE-CELL RNA-SEQUENCING & GENOTYPING OF AML PATIENTS WITH WT1-SUBCLONAL MUTATIONS TO ELUCIDATE CLONAL HETEROGENEITY
J. Niggemeyer¹, J. Bagnoli², L. Wange², M. Rothenberg-Thurley¹, W. Enard², K.H. Metzeler¹, ³
¹Experimental Leukemia and Lymphoma Research (ELLF) and Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Ludwig-Maximilians-Universität München, Germany; ²Anthropology and Human Genomics, Department Biology II, Ludwig-Maximilians-Universität München, Germany; ³German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁴Collaborative Research Center SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms, München, Germany

(32) SIMULATING CLONAL EVOLUTION IN ACUTE MYELOID LEUKEMIA (AML): BRIDGING THE GAP BY MATHEMATICAL MODELLING
Jan Banck¹, Dennis Görlich², Karsten Spiekermann¹
¹Ilrd Department of Medicine, University Hospital of Munich, Germany; ²Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany

(33) THE CYTOGENETIC PROFILE OF 94 PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
G. Vasilakis¹, M. Pagoni², S. Zachaki¹, P. Diamantopoulou¹, M. Margariti¹, D. Pantelia¹, M. Kalomiraki¹, C. Sambani, K.N. Manola¹
¹Laboratory of Health Physics, Radiobiology & Cytogenetics, National Center for Scientific Research (NCSR) "Demokritos", Athens, Greece; ²Hematology-Lymphoma Department-BMT Unit, Evangelismos Hospital, Athens, Greece

(34) FUNCTIONAL DOMINANCE OF CHIP-MUTATED HEMATOPOIETIC STEM CELLS IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATIONS
Christina A. Ortmann¹, Lena Dorsheimer¹, Khalil Abou-El-Ardat¹,², Jennifer Hoffrichter¹, Birgit Assmus³, Halvard Bönig⁴, Heike Pfeifer¹, Hans Martin¹, Tobias Schmidt⁵, Bernhard Brüne⁵, Sebastian Scheich¹, Julia Riemann¹, Stella Hermann⁶, Alexandra Dukat¹,⁶, Gesine Bug¹, Christian Brandts¹,², Sebastian Wagner¹,², Hubert Serve¹,², Michael A. Rieger¹,²
¹ Depart. of Medicine, Hematology/Oncology, Goethe University Hospital, Frankfurt; 2 German Cancer Consortium (DKTK) / German Cancer Research Center, Heidelberg; 3 Depart. of Medicine, Cardiology, Goethe University Hospital, Frankfurt; 4 Institute for Transfusion Medicine (BSD), Goethe University Hospital, Frankfurt; 5 Institute for Biochemistry I, Goethe University Hospital, Frankfurt; 6 Ambulantes Krebszentrum Schaubstrasse, Frankfurt
(35) DEVELOPING A MODEL SYSTEM FOR THE STUDY OF WILM’S TUMOR 1GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA
Naghmeh Niktoreh1, Rene Linka2, Constanze Wieker2, Christiane Walter1, Dirk Reinhardt1* and Helmut Hanenberg1,2*
1Clinic for Pediatrics III, University Hospital Essen, Essen, Germany. 2ENT Research; Laboratory, Heinrich Heine University, Düsseldorf, Germany. (*)Equal contribution

(36) IDH1 MUTATION EXACERBATES SYSTEM-LEVEL METABOLIC FLEXIBILITY THAT FAVORS MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION AND DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA
Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; LISBP, Université de Toulouse, CNRS, INRA, INSA, Toulouse, F-31077, France

II. AML – THERAPY

(37) AML AND MDS IN POPULATION OF UKRAINE IN POST-CHERNOBYL PERIOD (1991-2016)
Dept of Oncohematology, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR), National Academy of Sciences of Ukraine, Kyiv, Ukraine

(38) MULTICENTRE IMPLEMENTATION OF NEXT GENERATION SEQUENCING TO ACUTE MYELOID LEUKEMIA PATIENTS IN PETHEMA SPANISH COLLABORATIVE GROUP
C Sargas1, R Ayala2, C Chillón3, E Carrillo4, MJ Larrayoz5, C Bilbao6, J Serrano7, R Rodríguez-Veiga1, I Rapado1, R García-Sanz3, JA Pérez-Simón4, MJ Calasanz5, MT Gómez-Casares6, J Sanchez1, A Juarez2, M González3, C García-Calderón4, F Prosper6, C Rodríguez3, J Serrano7, P Montesinos1, J Martinez2, E Barragán1
1 HUyP La Fe, Valencia, España; 2 HU 12 de Octubre, Madrid, España; 3 HU de Salamanca, España, 4 HU Virgen del Rocío, Sevilla, España, 5 CIMA Lab Diagnostics, Universidad de Navarra, España, 6 HU de Gran Canaria Dr Negrín, Gran Canaria, España, 7 HU Reina Sofía, Córdoba, España

(39) OUTCOMES IN OLDER PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY AML (sAML) WHO ACHIEVE REMISSION WITH CPX-351 VERSUS 7+3 INDUCTION
S. Fader1, G.L. Uy2, G.J. Schiller2, J.E. Cortes4, E.K. Ritchie5, R.J. Ryan1, M. Chiarella1, A.C. Louie1
1Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3David Geffen School of Medicine of UCLA, Los Angeles, CA, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Weill Cornell Medical College of Cornell University, New York, NY, USA

(40) HIGH ALDEHYDE DEHYDROGENASE ACTIVITY AT DIAGNOSIS PREDICTS POOR OUTCOMES IN PATIENTS WITH t(8;21) ACUTE MYELOID LEUKEMIA
Lu Yang, Yan-Huan Zhang, Ya-Zhe Wang, Yan Chang, Ling-Di Li, Wen-Min Chen, Ling-Yu Long, Yue-Yun Lai, Hong-Hu Zhu, Ya-Zhen Qin
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China
MOLECULAR PROFILING AND OUTCOME OF PATIENTS WITH IDH1/2 MUTATED HEMATOLOGIC MALIGNANCIES AFTER TREATMENT WITH IVOSIDENIB OR ENASIDENIB


Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA; Department of Pharmacy, Moffitt Cancer Center, Tampa, FL, USA

OUTCOME OF ACUTE MYELOID LEUKEMIA WITH inv(3)(q21q26.2)/ t(3;3)(q21;q26.2). EXPERIENCE OF THE SPANISH PETHEMA AND CETLAM GROUPS


On behalf of PETHEMA and CETLAM cooperative groups

Hospital ICO-Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain. Hospital Universitari i Politècnic La Fe, Valencia, Spain. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Hospital ICO-Duran i Reynals, L'Hospital de la Llobregat, Spain. Hospital Reina Sofia, Córdoba, Spain.

Hospital Clínico Universitario, Valencia, Spain. Hospital Marqués de Valdecillas, Santander, Spain.

Hospital San Pedro de Alcantara, Cáceres, Spain. Hospital de la Vall d'Hebron, Barcelona, Spain.

Hospital Clinic, Barcelona, Spain. Hospital Clínico San Carlos, Madrid, Spain.

Hospital Clínico de Santiago, Santiago de Compostela, Spain. Hospital Josep Trueta, Girona, Spain.

Hospital Mutua de Terrassa, Terrassa, Spain

RAS MUTATIONS CONFER AN INCREASED RISK FOR RELAPSE IN PATIENTS WITH AML RECEIVING INDUCTION CHEMOTHERAPY

Brian Ball, MD, Aaron Goldberg, MD, Martin Tallman, MD, Eytan Stein, MD

Memorial Sloan Kettering Cancer Center, New York, USA

DO FRAILTY SCORES HELP DEFINING FITNESS OF ELDERLY AML PATIENTS AT DIAGNOSIS? A SINGLE CENTRE STUDY


Hematology, AOU Città della Salute e della Scienza di Torino, Italy. Dept. of Oncology and Hematology, Stem Cell Transplant Center, AOU Città della Salute e della Scienza di Torino, Italy. Unit of Cancer Epidemiology, CPO Piemonte, AOU Città della Salute e della Scienza di Torino, University of Turin, Italy

RESPONSE TO FRONT AND SECOND LINE TREATMENT IN PATIENTS WITH ACUTE NON LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE

Ashraf Alyamany, Safaa A. A. Khaled, Rabab Farghaly, Ashraf Z. Abd Allah

Department of Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. Department of Internal Medicine, Clinical Hematology Unit, Assiut University Hospital, Faculty of Medicine, Assiut University, South Egypt Cancer Institute, Assiut University. Department of Clinical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

PROGNOSING EFFICACY OF FLAG REGIMEN IN TREATMENT OF RELAPSED AND REFRACTORY AML


Dept. of Hematology, Almazov National Medical Research Centre, Russia
(47) DECITABINE AS SALVAGE THERAPY AFTER AZACITIDINE IN AML
Adolfo De La Fuente1, Paola Beneit2, Ana Muñoz Gama3, Antonio Sampol Mayol4, Karla Javier González5, Leticia Cañas de Dios6, Julio Dávila Valls7, Alicia Roldán Pérez8, Angela Figuera9, Cristina Barrenetxea Lekeu10, Ilziar Oiarzabal11, Sandra Suarez Ordoñez12, Susana Vives Polo13, Carmen Martínez Chamorro14, Rosa Coll Jordà15, Salut Brunet16, María Angeles Foncillas17, Bernardo González18, Antonio Díaz López19, Pau Montesinos20

(48) MRD LEVEL AFTER INDUCTION THERAPY IN NPM1 MUTATION AND RUNX1-RUNX1T1 POSITIVE AML IDENTIFIES HIGHER RISK OF RELAPSE PATIENTS
Federal Almazov North-West Medical Research Centre, Saint Petersburg, Russia

(49) HIGHLY SENSITIVE RESIDUAL DISEASE DETECTION IN ACUTE MYELOID LEUKEMIA USING ADVANCED ERROR CORRECTED DNA SEQUENCING
Laura W. Dillon1, Jake Higgins2, Lindsey N. Williams2, Jerald P. Radich3, Jesse J. Salk2,3, and Christopher S. Hourigan1
1National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 2TwinStrand Biosciences, Seattle, WA, and 3University of Washington, Seattle, WA, USA

(50) SPARING ANTI-BACTERIAL PROPHYLAXIS IN ACUTE MYELOID LEUKEMIA DURING POST INDUCTION APLASIA: RESULTS OF A RETROSPECTIVE SINGLE CENTER STUDY
Urbino1, Frairia C1, Audisio E1, Aydin S1, D’Ardìa S1, Messa E2, Iovino G1, Nicolino B1, Vitolo U1
1Department of Oncology and Hematology, Città della Salute e della Scienza di Torino, Turin, Italy; 2Hematology Unit, ASL-TO 4, Ivrea, Italy

(51) A MATHEMATICAL MODEL FOR RELAPSE PREDICTION IN AML PATIENTS BASED ON CONTINUING NPM1 MEASUREMENTS
H. Hoffmann1, I. Glauche1, C. Thiede2, M. Bornhäuser2, M. Kramer2, C. Röllig2, I. Roeder1,3
1Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TU Dresden, Germany; 2Medizinische Klinik und Poliklinik I, Faculty of Medicine Carl Gustav Carus, TU Dresden, Germany; 3National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany

(52) A MATHEMATICAL APPROACH TO ASSESS DURATION OF NEUTROPENIA WITHIN DIFFERENT INDUCTION REGIMENS IN ACUTE MYELOID LEUKEMIA (AML)
Jan Banck1, Dennis Görlich2
1Illrd Department of Medicine, University Hospital of Munich, Germany; 2Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany

(53) COMBINED INHIBITION OF THE MENIN-MLL CHROMATIN COMPLEX AND FLT3 ACTS SYNERGISTICALLY AGAINST FLT3 MUTANT LEUKEMIAS
M.Dzama, M.Taubert, K.Kunz, J.Rausch, CW.Chen, A.Mupo, M.Theobald, T.Kindler, R.P.Koche, GS Vassiliou, SA Armstrong, MWM Kühn1; (1IIId Department of Medicine, Johannes Gutenberg-University Mainz, Germany)

ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies
40
TARGETING CBP/β-CATENIN IN MDS/AML
E. Jiang, C. Nguyen, H.N. Kim, Samer Khaled, Tinisha McDonald, Guido Marcucci, JL. Teo, M. Kahn, YM. Kim

Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital of Los Angeles, University of Southern California, USA; Department of Molecular Medicine, and Developmental Cancer Therapeutics Program, Comprehensive Cancer Center., City of Hope Medical Center, USA; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope Medical Center, Duarte, USA; Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, USA

EXTRACELLULAR ATP AND CD39 REGULATES MITOCHONDRIAL FUNCTION AND CYTARABINE RESISTANCE THROUGH INTRINSIC PKA-PGC1 PATHWAY IN ACUTE MYELOID LEUKEMIA
N. Aroua, ML. Nicolau-Travers, T. Kaoma, N. Bonnefoy, F. Vergez, C. Récher and JE Sarry
Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; University of Toulouse, F-31077 Toulouse, France

ADRENOMEDULLIN RECEPTOR CALCRL DRIVES DRUG RESISTANCE OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA
N. Aroua, ML. Nicolau-Travers, T. Kaoma, N. Bonnefoy, F. Vergez, C. Récher and JE Sarry
Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; University of Toulouse, F-31077 Toulouse, France

Combined Inhibition of GCN5 and LSD1 PRIMES Acute Myeloid Leukemia for Retinoic Acid-Induced Differentiation

Department of Hematology/Oncology, Clinic of Internal Medicine II, Jena University Hospital, Jena, Germany; Institute of Molecular Cell Biology, Center for Molecular Biomedicine Jena (CMB), Jena University Hospital, Jena, Germany; Else-Kröner-Forschungskolleg, Jena, Germany; Leibniz-Institute on Aging, Fritz-Lipmann-Institute, Jena, Germany; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, USA; Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy; School of Natural Sciences, University of Stirling, Stirling, United Kingdom; 8 Military Institute of Hygiene and Epidemiology, Warsaw, Poland

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Hôpital Saint-Louis (AP-HP), Paris, FR; Centre Hospitalier de Versailles, Le Chesnay, FR; CHU Normandie de Caen, Caen, FR; Hôpital Saint-Antoine (AP-HP), Paris, FR; CHU Amiens, Amiens, FR; Hôpital Henri Mondor, Créteil, FR; Hôpital Saint-Louis, Paris, FR; Centre Hospitalier Lyon Sud, Lyon, FR; CHU de limoges, Limoges, FR; Pfizer Inc, Groton, CT, USA; Pfizer Inc, Cambridge, MA, USA; Pfizer Inc, Paris, France
(57) IMPACT OF EXCHANGE TRANSFUSION FOR PREVENTION OF EARLY DEATH IN A PEDIATRIC APL PATIENT WITH HYPERLEUKOCYTOSIS
Ulrike Hennewig¹, Natascha Ströter¹, Dieter Körholz¹, Nils von Neuhoff², Dirk Reinhardt¹, Ursula Creutzig³
¹University Hospital Giessen and Marburg, Giessen, Germany, ²University Children’s Hospital Essen, Essen, Germany, ³Hannover Medical School, Hannover, Germany

III. ALL – BIOLOGY

(58) PROGNOSTIC IMPORTANCE OF IKZF1 GENE DELETIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
N.Mihal, V.Vshyukova, A.Meleshko, N. Kasakevich, M. Shaverneva, O.Aleinikova
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Republic of Belarus

(59) DRAWING IN AF15Q14/CASC5 AND APOBEC3A/C IN LEUKEMOGENESIS
KV Bogdanov¹,², AY Zaritskey¹, M Takimoto²
Federal Almazov National Medical Research Centre¹, St. Petersburg, Russian Federation; Institute for Genetic Medicine², Hokkaido University, Sapporo, Japan

(60) INDUCIBLE RE-EXPRESSSION OF KLF4 IMPAIRS GROWTH OF PATIENT DERIVED ACUTE LYMPHOMA LEUKEMIA CELLS IN VIVO AND SENSITIZES THEM TOWARDS CHEMOTHERAPY
Wen-Hsin Liu¹, Larissa Schwarzkopf¹, Tobias Herold¹, Irmela Jeremias¹,²,³,⁴
¹Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; ²Collaborative Research Center SFB1243, Munich, Germany; ³German Cancer Consortium (DKTK), partner site Munich; ⁴Department of Oncology, Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität (LMU), Munich, Germany

(61) COMBINED INHIBITION OF MEK-SIGNALING AND BCL-2 PROMOTES SYNERGISTIC EFFECTS IN NRAS-MUTATED BCP-ALL CELLS
Department of Hematology/Oncology, Charité–Universitätsmedizin Berlin, Berlin, Germany. German Cancer Consortium (DKTK), Heidelberg, Germany. Department of Hematology/Oncology, Universitätsklinikum Schleswig-Holstein, Campus Kiel; Germany

(62) HETEROGENEOUS ACTIVITY AND SYNERGISTIC INTERACTION OF BH3-MIMETICS VENETOCLAX, S63845 & A1331852 IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
F. Stirnweis, F. Seyfried, K.-M. Debatin, and L. H. Meyer
Dept. of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany

(63) RNAi-SCREEN IDENTIFIES MEDIATORS OF STROMA-INDUCED RESISTANCE TO NOTCH AND mTOR-INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Felix Adams¹, Marc-Jens Kleppa¹, Martin May², Harald Genth², Zhixiong Li³, Christopher Baum¹, Axel Schambach¹,² and Adrian Schwarzer¹,³
¹Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany; ²Institute of Toxicology, Hannover Medical School, Hannover, Germany; ³Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School; Hannover, Germany; ⁴Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
IV. ALL – THERAPY

(64) TRENDS IN SURVIVAL OF YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SWEDEN AND USA
M Björkholm¹, G Edgren², H Hallböök³, PW Dickman²
¹Departments of Medicine Solna and ²Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden

(65) YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: THERAPY OPTIMIZATION IN REPUBLIC OF BELARUS
N.Mihal, E. Staliarova, L. Movchan, N. Kasakevich, Y.Kafanau, O.Aleinikova
Belarusion Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Republic of Belarus

(66) NON-INTENSIVE BUT NON-INTERRUPTIVE TREATMENT WITHOUT HIGH-DOSE BLOCKS IS EFFECTIVE STRATEGY FOR ADULT PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE FIRST INTERIM RESULTS OF THE RUSSIAN PROSPECTIVE MULTICENTER RALL-2016 STUDY
O.Gavrilina (0), E.Parovichnikova (0), V.Troitskaya (0), G.Baskhaeva (0), K. Zarubina (0), B.Biderman (0), I.Galtzeva (0), Yu.Davydova (0), T.Obukhova (0), A.Sokolov (0), P.Zeinalova (1) K.Kaplanov (2), O.Samoilova (3), V.Lapin (4), S.Bondarenko (5), E.Borisenkova(6), S.Kulikov, V.Savchenko
0 – National Research Center for hematology, Moscow; 1- National Oncology Center, Moscow; 2- Regional Oncology Hospital, Volgograd; 3 - Regional Hematology Center, N.Novgorod; 4 - Regional Hematology Center, Yaroslavl; 5 – Hematology and BMT Center, Saint Petersburg; 6- Regional Hematology Center, Kaluga; Russia

(67) MONITORING MEASURABLE RESIDUAL/RELAPSING DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
K. Wethmar¹*, S. Matern¹*, E. Esseling¹, M. Brüggemann², C. Schliemann¹, W.E. Berdel¹, G. Lenz¹, M. Stelljes¹
¹Dep. of Med. A, Hematology/Oncology, University Hospital Muenster, Germany; ²Dep. of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. (*)These authors contributed equally to this work

(68) NEXT GENERATION SEQUENCING AS THE WAY FOR IGH EARRAGEMENTMRD MONITORING IN B-ALL
K.Hrochova¹, L. Petrova¹, M. Lanska², F.Vrbacky², J. Horacek², P. Zak²
¹Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; ²4th Department of Internal Medicine - Haematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
V. IMMUNOTHERAPY

(69) EFFICIENT ELIMINATION OF CELLS FROM PATIENTS WITH DIFFERENT AML SUBTYPES BY DUAL-TARGETING TRIPLEBODY 33-16-123


1 Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Germany; 2Dept. of Biochemistry and Gene Center, LMU Munich, Germany; 3Dept. of Biology, University of Erlangen-Nuremberg, Germany; 4Westend Innovation, Munich, Germany; 5Dept. of Biochemistry, University of Zurich, Switzerland; 6Dept. of Internal Medicine 5, University of Erlangen-Nuremberg, Germany; 7Laboratory of Translational Cancer Immunology, Gene Center LMU Munich, Germany

(70) PRELIMINARY BIOMARKER AND PHARMACOKINETIC-RESPONSE RELATIONSHIPS IN A PHASE 1 STUDY OF AMG 330, A BISPECIFIC CD33 T-CELL ENGAGER (BiTE®) ANTIBODY CONSTRUCT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

C. E. Dos Santos, A. Anderson, M. Yago, R. Lesley, A. Stein, R. Walter, M. Lutteropp, Z. Yang, B. Mehta, M. Subklewe, F. Ravandi

1,2 Amgen Inc., South San Francisco and Thousand Oaks, CA, USA; 3City of Hope Medical Center, Duarte, CA, USA; 4Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 5Amgen Research (Munich) GmbH, Munich, Germany; 6Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany; 7The University of Texas MD Anderson Cancer Center, Houston, TX, USA

(71) ENHANCED PHAGOCYTIC ERADICATION OF LEUKEMIA CELLS BY COMBINATION OF AN FC-ENGINEERED CD19 ANTIBODY WITH CD47 IMMUNE CHECKPOINT BLOCKADE


1 Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts-University of Kiel, Kiel, Germany; 2Pediatric Hematology/Oncology, Christian-Albrechts-University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany; 3Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich, Germany (*shared senior authorship)

(72) ANTI-HUMAN CD117 CAR T-CELLS EFFICIENTLY ELIMINATE HEMATOPOIETIC STEM AND CD117-POSITIVE AML CELLS

R. Myburgh, J. Kiefer, N. F. Russkamp, A. Simonis, S. Pfister, C. Magnani, C. M. Wilk, A. M. Müller, M. van den Broek, B. Becher, D. Neri and M. G. Manz

1 Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland, 2Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland, 3Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

(73) ADGRE2 SHOWS A FAVORABLE EXPRESSION PROFILE FOR CAR-TARGETING IN ACUTE MYELOID LEUKEMIA


1 Dept. of Hematology, Hannover Medical School, Germany; 2Dept. of Internal Medicine, Municipal Hospital, Braunschweig, Germany; 3Dept. of Medicine II, University Hospital Hamburg-Eppendorf, Germany; 4Dept. of Hematology, Siloah Krankenhaus, Hannover, German; 5Dept. of Internal Medicine V, Klinikum Luedenscheid, Germany
VI. PEDIATRIC ACUTE LEUKEMIAS

(74) NG2 PREDICTIVE VALUE FOR PRESENCE OF KMT2A-REARRANGEMENTS DIFFERS AND DEPENDS ON AGE AND ACUTE LEUKEMIA TYPE
A. Chitanava1, O. Illarionova1, S. Lebedeva1, L. Baidun2, Yu. Olishanskaya1, E. Zerkalenkova1, A. Popov1
1National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation; 2Russian Children Clinical Hospital, Moscow, Russian Federation

(75) THE MLL-RECOMBINOME OF PEDIATRIC ACUTE LEUKEMIA IN RUSSIAN FEDERATION
Lab. of cytogenetics and molecular genetics, National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

(76) INTRON RETENTION IN KMT2A-MLLT3 FUSION TRANSCRIPT IN PEDIATRIC ACUTE LEUKEMIA
Lab. of cytogenetics and molecular genetics, National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

(77) VERIFICATION OF PEDIATRIC BCR-ABL1-LIKE ALL CASES BY REAL-TIME PCR
G. Tsaur1,2,3, T. Mukhacheva2, P. Sibiryakov1, S. Kovalev2, Yu. Olishanskaya5, O. Soldatkin4, A. Popov4, T. Verzhbitskaya1, A. Vlasova1, O. Arakaev1, L. Saveliev1,3, L. Fechina1
1Regional Children's Hospital, Research Institute of Medical Cell Technologies, Ekaterinburg, Russia; 2Ural Federal University named after the First president of Russia B.N. Yeltsin, Ekaterinburg, Russia; 3Ural State Medical University, Ekaterinburg, Russia; 4National Medical Research Centre of Pediatric Hematology, Oncology and Immunology named after D. Rogachev, Moscow, Russia

(78) EFFICACY OF EPIGENETIC THERAPY WITH INTENSIVE CHEMOTHERAPY IN TREATMENT CHILDHOOD ACUTE MYELOID LEUKEMIASE A. Popa1, V. Nemirovchenko1, O. Tiganva2, B. Kurdyukov1, G. Mentkevich1
1Dept. of Hematology/Oncology Pediatric Oncology and Hematology Research Institute, N.N.Blokhin Russian Cancer Research Center, Moscow, Russia; 2Morozovskaya Children's Clinical Hospital, Moscow, Russia

(79) ANALYZING TRANSCRIPTIONAL PROFILES OF CHILDHOOD ALL AT SINGLE CELL RESOLUTION
L. E. Wange1, S. Köhrer3, J. W. Bagnoli1, E. Z. Özdemir2, A. Janjic1, J. Geuder1, G. Mann3, I. Jeremias2, R. Panzer-Grümmayer3, W. Enard1,2,3 shared last author
1Ludwig Maximilians University, Munich; 2Helmholtz Center, Munich; 3Children's Cancer Research Institute, St. Anna Kinderspital, Medical University Vienna, Austria

(80) THE DEFINITION OF THE MRD IS THE MAIN STRATIFICATION TOOL FOR RISK GROUPS DETECTION IN CHILDREN WITH B-ALL
M. Shervashidze, A. Popa, O. Beznos, N. Batmanova, B. Kurdyukov, G. Mentkevich
CN.N. Blokhin Cancer Research Center Moscow, Russia
(81) **EPGENETIC THERAPY ALLOWS TO IMPROVE SURVIVAL CHILDREN WITH ACUTE MYELOID LEUKEMIA**

V.S. Nemirovchenko, A.V. Popa, G.L. Mentkevich

Pediatric Oncology and Hematology Institute, Federal N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

(82) **MIR-497~195 CLUSTER HAS TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ALL**

E. Boldrin¹, E. Gaffo², S. Demir¹, J. Zinngrebe¹, K-M. Debatin¹, G. te Kronnie³, S. Bortoluzzi², L.H. Meyer¹

¹ Dept. of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Germany. ² Dept. of Molecular Medicine, Padua University, Italy. ³ Dept. of Women's and Children's Health, Padua University, Italy

(83) **TP53 ALTERATIONS AND GENE-EXPRESSION PROFILING OF P53 PATHWAY GENES IN PEDIATRIC ACUTE MYELOID LEUKEMIA**

DGJ. Cucchi¹,², C. Bachas¹,², K. Klein¹, S. Huttenhuis¹, CM. Zwaan³, GJL. Kaspers¹,⁴, J. Cloos¹,².

¹Pediatric Hematology and ²Hematology, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands; ³Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands; ⁴Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

(84) **HYPERLEUKOCYTOSIS IN CHILDREN WITH ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER EXPERIENCE**


Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

(85) **CD1a AND T-CELL RECEPTORS EXPRESSION PREDICTS OUTCOME IN CHILDHOOD T-LINEAGE ALL**

A. Popov¹, O. Illarionova¹, A. Chervova¹, T. Verzbitskaya², L. Fechina², J. Roumianteva¹, G. Henze³, A. Karachunsky¹

¹National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia; ²Regional Children’s Hospital, Ekaterinburg, Russia; ³ Klinik für Pädiatrische Onkologie und Hämatologie, Charité CVK, Universitätsmedizin Berlin, Germany
GENERAL INFORMATION

Scientific Program:  Sunday, February 24 – Wednesday, February 27, 2019

Venue:  Klinikum Großhadern
Hörsaaltrakt
Marchioninistraße 15
81377 Munich, Germany

Official Language:  English

Scientific Program:  All Main Sessions, Satellite Symposia and Meet-the-Professor Sessions are CME-certified sessions. Take the opportunity and hear the internationally most recognized experts, discuss the most relevant clinical questions, and earn CME credits.

Free Oral and Poster Presentation:  Additional contributions will be presented in an oral session (Best of Free Contributions) and as posters. Poster Session will be held on Monday, Feb. 25, 2019, Best of Free Contributions’ Session will be held on Tuesday, Feb. 26, 2019.

How to Register:  All registrations must be done by e-mail
The easiest way to register is by electronic registration via our website:
www.acute-leukemias.de

Official Homepage:  All necessary details about the registration modus, registration fees, and registration deadlines are listed below and at www.acute-leukemias.de

Organizing Office:  Beate Buske-Kosel, M.A.
Am Webstuhl 5
D-59227 Ahlen, Germany
Phone:  +49-(0)2382-76 01 457
Fax:  +49-(0)2382-76 01 458
e-mail:  info@acute-leukemias.de
GENERAL INFORMATION

Registration Deadlines and Registration Fee:

- **“Early” registration fee:** € 210
  Registration and payment before December 31, 2018

- **“Advance” registration fee:** € 250
  Registration and payment: after January 1, 2019, but before February 22, 2019

- **“Late” and “On-site” registration fee:** € 290
  Registration and payment after February 22, 2019 or on-site

Method of Payment:

Advance payment can be made by check or wire transfer to following bank account:

- **Account Holder:** Verein für Leukämieforschung und Therapie e.V.
- **Bank:** Sparkasse Münsterland Ost
- **Bank Address:** 48135 Münster
- **Bank Code:** 400 501 50
- **Account No:** 1900 2468
- **Key word:** ACUTE LEUKEMIAS XVII - 2019
- **IBAN:** DE 64 400 501 5000 1900 2468
- **BIC-Code:** WELADED1MST

To identify your payment correctly all payments must carry the name of the participant and the key word ACUTE LEUKEMIAS XVII – 2019. Please note that on-site payment by credit card is not possible!

Services included:

The registration includes admission to all scientific sessions, the reception on Sunday evening, February 24, 2019, lunch buffets and poster buffet, hot & cold drinks, and the Abstract Booklet.

Free access to all sessions:

- Invited Speakers, Chairmen, and Members of the Scientific Committees
- Participating Members of the AMLCG Study Group
- Members of the LMU and TUM Munich
- Members of the Helmholtz-Zentrum Munich
- Members of the TZM Project Group „Akute Leukämie, MDS und MPS“
- Former Members of the SFB 684 Munich
- Students and Nurses (confirmation required)
- Invited Representatives of the Participating Corporate Partners (confirmation required)
PRIZES AND AWARDS:

Awards:

Again, 2 Poster Awards of € 500 and the 3 Best-of-Free-Contributions Awards will be granted to young scientists whose abstract has been accepted for presentation in the poster session.

The Leukemia Clinical Research Award 2019 (LCRA) which is endowed with € 7,500 will be granted to a young investigator presenting a scientific paper in the field of clinical or preclinical research. Candidates must submit their application until the submission deadlines.

Prize Giving Ceremony: Poster Awards, 3 Best of Free Contributions and LCRA 2019, Tuesday, February 26, 16.30-17.30

Poster Viewing: Monday, February 25, 2019: 13.00 - 18.00
Tuesday, February 26, 2019: 09.00 and 18.00

Poster Presentation and Discussion Session: All poster presenters are expected to attend ISALXV personally* and participate in:

● Main Session V (Poster Session) on Monday, February 25, 2019 between 16.00 and 18.00 for poster presentation and discussion.

● Main Session IX (Prize Giving Ceremony Poster Awards and Oral Presentations of 3 Best of Free Contributions) taking place on Tuesday, February 26, 2019 between 16.30 and 17.30.

(*In case a poster presenter is not able to personally attend the symposium and Main Sessions V and IX he is asked to provide a person who can take over his part and inform the Organizing Office about his representative)

CERTIFICATES/CME A certificate of attendance will be available on-site for all officially registered participants (ISALXVII).
CERTIFICATE OF ATTENDANCE:

● A certificate of attendance will be available on-site for all officially registered participants of the International Symposium ACUTE LEUKEMIAS XVI (ISALXVII).

An application for Continuing Medical Education (CME) of ISALXVII has been made to:

● The Bayerische Landesärztekammer (BLAEK) has granted the following CME points:
  
  24.2.2019: 7 CME points
  25.2.2019: 6 CME points
  26.2.2019: 7 CME points
  27.2.2019: 4 CME points

HOTELS AND ACCOMODATION FACILITIES FOR NATIONAL and INTERNATIONAL ATTENDEES

Thank you for attending ISALXVI 2017. To facilitate your planning and help you make your stay as pleasant as possible, the Munich Tourism Team of München Tourismus is happy to offer you a great variety of Munich hotels, pensions, guesthouses and youth hostels. According to your preferences and criteria they will try to find for you the best offer at the most reasonable price performance ratio.

Service Requests can be either made by Phone, Fax or Email

Phone: +49 89 233-96500
Monday –Friday: 09.00 – 17.00 h
Fax: +49 89 233-30030
Email: tourismus.gs@muenchen.de

HOTELS AND ACCOMODATION FACILITIES FOR NATIONAL and INTERNATIONAL INVITED SPEAKERS AND FACULTY:

To facilitate your planning and help you make your stay most pleasant and comfortable, the ISALXVII ORGANIZING OFFICE TEAM (info@acute-leukemias.de) is happy to assist you personally in everything related to your stay and will contact you unrequested during the early planning phase.
SUNDAY, February 24, 2019, 20.00 – 22.00

Social Event

*Welcoming Reception at LeMeridien*

**Address:**
*Hotel LeMERIDIEN*
Bayerstraße 4
D-80335 Munich

**Admission:** (Free Access)
All officially registered participants of the meeting, accompanying persons, and participating corporate partners are cordially invited to participate in the *Welcoming Reception* which will be held in the banqueting hall of *LeMERIDIEN*.

Since space is limited advance reservations are obligatory either at [www.acute-leukemias.de](http://www.acute-leukemias.de) or during the official opening hours at the ISALXVII registration desk. Please note that priority will be given to those that register early).

A free-of-charge Shuttle Bus Service will be available for all participants joining the Welcome Reception at LeMeridien after the end of Satellite II starting from the symposium venue (Back exit Hörsaaltrakt; Details will be announced on site)

**Directions – Public Transport:**
Starting at Klinikum Großhadern U6 to Sendlinger Tor. From Sendlinger Tor U1/U2 to Munich Main Station. Starting at Marienplatz: All S-lines which stop at Munich Main Station; from there it is a 5 minutes’ walk from the south exit
TUESDAY, February 26, 19.30-22.00

Social Event

Social Evening and Informal Dinner at DEUTSCHES MUSEUM

Address:
Deutsches Museum Verkehrszentrum, Am Bavaria Park 5, 80339 München

Admission:
Free Guaranteed Admission: Invited speakers, Chairmen, and Members of the Scientific Committees (Reservation Required)

Regular Entry Fee:
€ 15.00: Students, Nurses and Students
€ 25.00: All other officially registered Participants of ISALXVII

Since space is limited advance reservations are obligatory either at www.acute-leukemias.de or during the official opening hours at the ISALXVII registration desk. Please note that priority will be given to those that register early).

A free-of-charge Shuttle Bus Service will be available for all participants joining the Social Evening at the Deutsches Museum after the end of Satellite VIII starting from the symposium venue (Back exit Hörsaaltrakt; Details will be announced on site)

Directions - Public Transport:
U-Bahn U4/U5 exit at Schwanthalerhöhe, Bus 134 exit at Theresienhöhe. Detailed directions will be handed out at the registration desk
CORPORATE SUPPORT

The support of ACUTE LEUKEMIAS XVII by following partners is gratefully acknowledged (alphabetical order)

Gold Circle Corporate Members (Satellite Symposia)
AbbVie Deutschland GmbH SAT II         Sunday,   Feb 24, 2019: 18.15-19.15
AMGEN AG SAT I          Sunday,   Feb 24, 2019: 17.00-18.00
ASTELLAS Pharma GmbH SAT VI        Tuesday, Feb 26, 2019: 13.00-14.00
Celgene GmbH SAT VII                Tuesday, Feb 26, 2019: 16.30-17.30
Daichi Sankyo SAT IV                Monday, Feb 25, 2019: 17.00-18.00
Jazz Pharmaceuticals SAT III         Monday, Feb 25, 2019: 12.45-13.45
Pfizer GmbH SAT VIII                 Tuesday, Feb 26, 2019: 17.45-18.45
Roche Pharma GmbH SAT V             Monday, Feb 25, 2019: 18.15-19.15

Silver Circle Corporate Members (MTP Session / Evening Symposium)
GILEAD SCIENCES GmbH                Monday, Feb 25, 2018: 13.00-13.45
Vector Therapeutics, Inc.            Monday, Feb 25, 2018: 19.30-21.00

Other Corporate Support:
AGIOS Pharmaceuticals                Poster Prizes
GILEAD SCIENCES GmbH                 AGIHO Symposium

Participating Companies in the Commercial Exhibition:
AbbVie Deutschland GmbH & Co KG       Lipomed GmbH
AMGEN GmbH                           Neovii Biotech GmbH
ASTELLAS Pharma GmbH                 Novartis Pharma GmbH
Celgene GmbH                          Pfizer GmbH
Daichi Sankyo                         Roche Pharma GmbH
GILEAD SCIENCES GmbH                  Servier Deutschland GmbH
HELSINN Healthcare SA                 TEVA GmbH
HISS GmbH                             Vector Therapeutics, Inc.
Jazz Pharmaceuticals

German Research Sponsors:
ELN Foundation – European ▪ LeukemiaNet
HelmholtzZentrum München
## CORPORATE SUPPORT

**Gold Circle Corporate Members (Satellite Symposia):**

<table>
<thead>
<tr>
<th>Abbvie Deutschland GmbH</th>
<th>SAT II: Sunday, Feb 24, 2019 € 25.000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen GmbH</td>
<td>SAT I: Sunday, Feb 24, 2019 € 25.000</td>
</tr>
<tr>
<td>Astellas Pharma</td>
<td>SAT VI: Tuesday, Feb 26, 2019 € 25.000</td>
</tr>
<tr>
<td>Celgene GmbH</td>
<td>SAT VII: Tuesday, Feb 26, 2019 € 25.000</td>
</tr>
<tr>
<td>Daiichi Sankyo GmbH</td>
<td>SAT IV: Monday, Feb 25, 2019 € 25.000</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals Germany GmbH</td>
<td>SAT III: Monday, Feb 25, 2019 € 22.000</td>
</tr>
<tr>
<td>Pfizer GmbH</td>
<td>SAT VIII: Tuesday, Feb 26, 2019 € 25.000</td>
</tr>
<tr>
<td>Roche Pharma GmbH</td>
<td>SAT V: Monday, Feb 25, 2019 € 25.000</td>
</tr>
</tbody>
</table>
Silver Circle Corporate Members (MTP Session):

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilead Sciences GmbH</td>
<td>€ 15,000</td>
</tr>
</tbody>
</table>

Bronze Circle Corporate Members (Industrial Exhibition):

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbvie Deutschland GmbH</td>
<td>€ 4,500</td>
</tr>
<tr>
<td>Amgen GmbH</td>
<td>€ 3,600</td>
</tr>
<tr>
<td>Daiichi Sankyo GmbH</td>
<td>€ 7,880</td>
</tr>
<tr>
<td>Helsinn Healthcare</td>
<td>€ 3,500</td>
</tr>
<tr>
<td>HISS Diagnostics GmbH</td>
<td>€ 2,400</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals Germany GmbH</td>
<td>€ 3,940</td>
</tr>
<tr>
<td>Lipomed GmbH</td>
<td>€ 2,400</td>
</tr>
<tr>
<td>Neovii Biotech GmbH</td>
<td>€ 2,400</td>
</tr>
<tr>
<td>Novartis Pharma GmbH</td>
<td>€ 3,500</td>
</tr>
<tr>
<td>Pfizer GmbH</td>
<td>€ 2,400</td>
</tr>
<tr>
<td>Company</td>
<td>Support Type</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>Roche Pharma GmbH</td>
<td></td>
</tr>
<tr>
<td>Servier Deutschland GmbH</td>
<td></td>
</tr>
<tr>
<td>TEVA GmbH</td>
<td></td>
</tr>
<tr>
<td>Vector Therapeutics</td>
<td></td>
</tr>
</tbody>
</table>

**Other Corporate Support:**

<table>
<thead>
<tr>
<th>Company</th>
<th>Support Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGIOS</td>
<td>Sponsors Poster Prizes</td>
<td>€ 1,000</td>
</tr>
<tr>
<td>AGIOS</td>
<td>Advertisement Annals of Hematology</td>
<td>€ 1,500</td>
</tr>
<tr>
<td>Gilead Sciences GmbH</td>
<td>Support AGIHO Symposium</td>
<td>€ 5,000</td>
</tr>
<tr>
<td>Helsinn Healthcare</td>
<td>Advertisement Annals of Hematology</td>
<td>€ 1,500</td>
</tr>
</tbody>
</table>

**German Research Sponsors:**

<table>
<thead>
<tr>
<th>Company</th>
<th>Support Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>HelmholtzZentrum München</td>
<td></td>
<td>€ 5,000</td>
</tr>
<tr>
<td>ELN Foundation</td>
<td></td>
<td>€ 1,000</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08:30-08:45</td>
<td>WELCOME ADDRESS</td>
<td></td>
</tr>
<tr>
<td>08:45-09:45</td>
<td>MS III: THOMAS BÜCHNER LECTURE</td>
<td></td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>EDUCATIONAL SYMPOSIUM Infectious Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Working Party of the DGHO (AGIHO)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COFFEE BREAK 09.45-10.15</td>
<td></td>
</tr>
<tr>
<td>10:15-12:00</td>
<td>MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LUNCH BREAK 12.00 – 14.00</td>
<td></td>
</tr>
<tr>
<td>12:30-14:15</td>
<td>MS I: Epigenetic Changes In Acute Leukemias</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coffee Break 14.15–14.45</td>
<td></td>
</tr>
<tr>
<td>14:45-16:45</td>
<td>MS II: Characterization of Leukemic Stem Cells</td>
<td></td>
</tr>
<tr>
<td>14.00-16.00</td>
<td>MS IV: Novel Approaches and Targeted Therapies in AML</td>
<td></td>
</tr>
<tr>
<td>16.00-18.00</td>
<td>POSTERS – 16.00-18.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>POSTER DISCUSSION with Wine and Bread</td>
<td></td>
</tr>
<tr>
<td></td>
<td>POSTERS 18.00 – 19.15</td>
<td></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>Satellite Symposium I AMGEN GmbH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium II AbbVie Deutschland GmbH</td>
<td></td>
</tr>
<tr>
<td>18.15–19.15</td>
<td>Satellite Symposium V ROCHE PHARMA GmbH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>POSTER VIEWING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Possibility for further Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>POSTER POSSIBILITIES FOR FURTHER DISCUSSION</td>
<td></td>
</tr>
</tbody>
</table>

**SUNDAY, February 24, 2019**

<table>
<thead>
<tr>
<th>Lecture Hall III (live streaming IV/V)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:45 WELCOME ADDRESS</td>
</tr>
<tr>
<td>08:45-09:45 MS III: THOMAS BÜCHNER LECTURE</td>
</tr>
<tr>
<td>10:00-12:00 EDUCATIONAL SYMPOSIUM Infectious Diseases</td>
</tr>
<tr>
<td>10:15-12:00 MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis</td>
</tr>
<tr>
<td>12:30-14:15 MS I: Epigenetic Changes In Acute Leukemias</td>
</tr>
<tr>
<td>14:45-16:45 MS II: Characterization of Leukemic Stem Cells</td>
</tr>
<tr>
<td>16.00-18.00 POSTERS – 16.00-18.00</td>
</tr>
<tr>
<td>17.00-18.00 Satellite Symposium I AMGEN GmbH</td>
</tr>
<tr>
<td>18.15–19.15 Satellite Symposium II AbbVie Deutschland GmbH</td>
</tr>
</tbody>
</table>

**MONDAY, February 25, 2019**

<table>
<thead>
<tr>
<th>Lecture Hall III (live streaming IV/V)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:45 WELCOME ADDRESS</td>
</tr>
<tr>
<td>08:45-09:45 MS III: THOMAS BÜCHNER LECTURE</td>
</tr>
<tr>
<td>10:00-12:00 EDUCATIONAL SYMPOSIUM Infectious Diseases</td>
</tr>
<tr>
<td>10:15-12:00 MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis</td>
</tr>
<tr>
<td>12:30-14:15 MS I: Epigenetic Changes In Acute Leukemias</td>
</tr>
<tr>
<td>14:45-16:45 MS II: Characterization of Leukemic Stem Cells</td>
</tr>
<tr>
<td>16.00-18.00 POSTERS – 16.00-18.00</td>
</tr>
<tr>
<td>17.00-18.00 Satellite Symposium I AMGEN GmbH</td>
</tr>
<tr>
<td>18.15–19.15 Satellite Symposium II AbbVie Deutschland GmbH</td>
</tr>
</tbody>
</table>

**Lecture Hall III**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:45</td>
<td>WELCOME ADDRESS</td>
</tr>
<tr>
<td>08:45-09.45</td>
<td>MS III: THOMAS BÜCHNER LECTURE</td>
</tr>
<tr>
<td>10:00-12.00</td>
<td>EDUCATIONAL SYMPOSIUM Infectious Diseases</td>
</tr>
<tr>
<td></td>
<td>Working Party of the DGHO (AGIHO)</td>
</tr>
<tr>
<td></td>
<td>COFFEE BREAK 09.45-10.15</td>
</tr>
<tr>
<td>10.15-12.00</td>
<td>MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis</td>
</tr>
<tr>
<td></td>
<td>LUNCH BREAK 12.00 – 14.00</td>
</tr>
<tr>
<td>12:30-14:15</td>
<td>MS I: Epigenetic Changes In Acute Leukemias</td>
</tr>
<tr>
<td></td>
<td>Coffee Break 14.15–14.45</td>
</tr>
<tr>
<td>14:45-16:45</td>
<td>MS II: Characterization of Leukemic Stem Cells</td>
</tr>
<tr>
<td>16.00-18.00</td>
<td>POSTERS – 16.00-18.00</td>
</tr>
<tr>
<td></td>
<td>POSTER DISCUSSION with Wine and Bread</td>
</tr>
<tr>
<td></td>
<td>POSTERS 18.00 – 19.15</td>
</tr>
<tr>
<td></td>
<td>POSTER VIEWING</td>
</tr>
<tr>
<td></td>
<td>Possibility for further Discussion</td>
</tr>
<tr>
<td></td>
<td>POSTER POSSIBILITIES FOR FURTHER DISCUSSION</td>
</tr>
</tbody>
</table>
ACUTE LEUKEMIAS XVII – Munich, February 24-27, 2019

FLOOR PLAN – Level 02
POSTER EXHIBITION AREA
LUNCH AND LOUNGE AREA

POSTER EXHIBITION and POSTER PRESENTATION
Mounting, Viewing, Exhibition, Prize Giving Session, Dismantling

Sunday, February 24, 2019: 12:00 PM – 06:30 PM (Mounting)
Monday, February 25, 2019: 08:30 AM – 02:00 PM (Mounting)
Monday, February 25, 2019: 04:00 PM – 06:00 PM (Viewing and Discussion)
Tuesday, February 26, 2019: 08:30 AM – 04:30 PM (Viewing)
Tuesday, February 26, 2019: 04:30 PM – 05:30 PM; (Main Session IX: Prize Giving Ceremony Poster Awards and 3 of Best Free Contribution Awards)
Wednesday, February 27, 2019: 08:30 AM – 01:00 PM; (Dismantling)

LUNCH and COFFEE BREAKS

Sunday: February 24, 2019:
Coffee Break: 12:00 PM – 12:30 PM; 02:15 PM – 02:45 PM; 04:45 PM – 05:00 PM

Monday: February 25, 2019:
Coffee Break: 09:45 PM – 10:15 PM; Lunch Break: 12:00 PM – 02.00 PM; Poster Buffet with Cheese and Wine: 04:00 PM – 06.00 PM

Tuesday: February 26, 2019:
Coffee Break: 10:30 AM – 10:50 AM; Lunch Break: 12:30 PM – 02.00 PM; Coffee Breaks: 03:45 – 04.15 PM; 05:30 PM – 05:45 PM;

Wednesday: February 27, 2019: Coffee Break: 10:30 AM – 11.00 AM
SCIENTIFIC LOCAL ORGANIZING COMMITTEE:
Prof. Dr. Wolfgang Hiddemann, Munich (Chairman)
Prof. Dr. Dr. Michael von Bergwelt, Munich
Prof. Dr. Karsten Spiekermann, Munich
Prof. Dr. Irmela Jeremias, Munich
Prof. Dr. Marion Subklewe, Munich
PD Dr. Klaus Metzeler, Munich

ORGANIZING OFFICE:
Beate Buske-Kosel, M.A.
Phone: +49-(0)2382-76 01 457
Fax: +49-(0)2382-76 01 458
e-mail: info@acute-leukemias.de

COORDINATING OFFICE:
Doris Braun
Phone: +49-89-4400 43986
Fax: +49-89-4400 43970
e-mail: Doris.Braun@med.uni-muenchen.de